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ABSTRACT 
 
ESTABLISHING COMMUNITY AND RESEARCH TRUST IN PUBLIC HEALTH 
USING SERVICE-ORIENTED ARCHITECTURE (SOA) 
 
by Juanita H. Mah 
 
One of the major challenges of community-based research is recruitment of community 
members who will participate in clinical trials, continue for the duration of the trial, and 
provide accurate sensitive personal information.  This challenge can be overcome by 
establishing greater trust between researchers and communities. 
 
This study focuses on a system to address trust issues between the San Jose Hispanic 
community and clinical researchers.  It describes a methodology for translating non-
functional wants and needs into technical requirements that are used as input to a Service-
Oriented Architecture (SOA) approach to design a solution.  Unlike a typical SOA that is 
derived from a single enterprise’s business goals and processes, this solution is based on 
multiple stakeholder goals and general clinical trial processes. 
 
The resulting architecture focuses on improving communication between researchers and 
communities and is validated by mapping the technical requirements against a trust-
building model and modeling the solution using Petri nets. 
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I  Introduction 
 
Clinical researchers use clinical trials to evaluate the effectiveness and safety of 
medications or medical devices by monitoring their effects on large groups of people [1].   
Clinical trials may be used to test new approaches for preventing, detecting, diagnosing, 
or treating disease and are concerned with issues such as drug safety, appropriate dosages 
and dose administration, efficacy, and treatment side effects [2]. 
 
Clinical trials may be sponsored by a variety of public and private concerns, such as 
government health agencies, hospital or university researchers, independent researchers, 
pharmaceutical companies, or biomedical device companies.  Plans for a clinical trial 
must first be approved by the federal government.  After approval, trial execution and 
results are monitored by government agencies.  Typically, these agencies approve or 
disapprove new treatments based on the results of the trial [1], [2], [3].  
 
A study may include multiple clinical trial phases.  Each phase has its own purpose; and 
the number of participants increases with each subsequent phase.  The duration of a phase 
varies.  Typically, the earlier phases last one to two years, while the later phases are 
longer and can last 5 years or more [3].  
 
Clinical trials can involve patients as well as healthy individuals.  In most cases, these 
research subjects are volunteers; but sometimes they might be paid.  Each candidate must 
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meet certain criteria in order to be eligible to participate in a study.  In addition, 
researchers must ensure that all candidates are aware of the benefits and risks associated 
with participating in the trial prior to enrolling in the trial.  The process of ensuring that 
participants know key facts about the trial is known as informed consent.  The intent of 
informed consent is to ensure that the rights and welfare of human subjects are protected 
[2], [3].   
 
One of the major challenges of clinical research is the recruitment and retention of 
participants in clinical trials.  Enough qualified candidates must be enrolled to ensure a 
valid sample size.  Participants must be fully informed of the potential risks as well as the 
benefits of participating.  The program must be designed to effectively and accurately 
elicit potentially sensitive personal information.  Moreover, the program must be 
executed in a manner that ensures continued participation by trial subjects for the 
duration of the trial.  Ineffective recruitment and retention practices can elongate trial 
phases and increase treatment development costs.  
 
One way to facilitate recruitment and retention is by taking actions to establish greater 
trust between researchers and a community.  These actions can be incorporated into each 
major stage of a clinical trial phase.  For example, during the planning stage, the 
informed consent process might be customized to meet the needs of a community.  
During the execution stage, actions might be taken to improve communication and 
information flow among those directly and indirectly involved.  Later, after a trial is 
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completed, steps might be taken to inform participants of the results and to collaborate 
with them in planning the next trial phase. 
 
A. Thesis Goals. 
This thesis focuses on a software solution to address trust-building issues between 
clinical researchers and a community where clinical trials are being conducted.  A 
community is “an association of people who gather together to share a common interest 
and/or relevancy during a period of time” [4].  A community may be based on common 
points of reference, such as geography, ethnicity, religion, culture, interests, or 
organization.  This thesis specifically uses the San Jose Hispanic community as the basis 
for a case study to determine solution requirements and evaluate the results of the study. 
 
The primary goal of this thesis is to demonstrate how various modeling techniques can be 
used to architect a flexible software solution that addresses a shared need between diverse 
stakeholders with different but related goals.  The output of the study will be a software 
system architecture that is intended to improve communication between the researchers 
and members of the community.  By establishing structured communications among 
clinical trial participants, clinical researchers should expect greater trust and 
collaboration, thereby increasing participation rates, yielding more valid data input, and 
facilitating subsequent research activities.   
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First, a methodology will be developed to derive a set of technical requirements for that 
system from non-functional wants and needs.  Next, to ensure strong linkage and 
traceability between the business goals of clinical trial participants and the software 
solution, the architecture will be developed using a Services-Oriented Architecture 
(SOA) approach.  The architecture definition will be in the form of a Service Model, 
Goal-Service Model, and Design Model.  Last, selected service components will be 
modeled using Petri nets as part of solution validation. 
 
B. Expected Contributions to the Body of Knowledge. 
This study proposes a methodology for transforming non-functional domain-specific 
wants and needs, such as trust building, into technical requirements that can be 
implemented via a software system.  This methodology will be generalized so it can be 
applied to other non-functional problem sets. 
 
Currently, an SOA focuses on a single enterprise’s information technology needs and 
strives to establish traceability from that enterprise’s vision and business goals to 
individual services to be developed or called by the enterprise solution.  This study 
extends existing SOA approaches in two ways.  First, this study will demonstrate how an 
SOA approach can be used to define an architectural solution for a general problem 
domain, i.e., the clinical trials process, rather than for a specific enterprise.  Second, this 
study will show how to define an SOA to achieve common goals of multiple 
stakeholders, with traceability back to their respective visions and goals.  Last, this study 
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explores the use of Petri nets to model web services.  Petri nets will be used to model 
individual services and relationships among web services within an SOA.  Petri net 
simulations can be used to validate the architecture’s correctness.  These models can also 
be used to identify potential implementation issues such as deadlocks and concurrency.   
 
C. Organization of This Thesis. 
The remainder of this paper is organized into three parts:  The first part contains four 
sections and provides background information.  In Section II, some of the current 
challenges associated with establishing trust between clinical researchers and 
communities as well as recommended solutions will be described.  Section III examines 
specific health and trust issues associated with the San Jose Hispanic community and 
introduces a case study.  Section IV focuses on the current state of the art and identifies 
some existing software that is used by clinical researchers to design and manage clinical 
trials.  Section V is a brief overview of SOA and its benefits.  It also contains a 
description of Service-Oriented Modeling and Architecture (SOMA), an approach for 
modeling an SOA.   
 
The second part consists of two sections where a proposed software solution will be 
derived.   In Section VI, a methodology for translating non-functional wants and needs 
into technical requirements that can be implemented will be demonstrated.  Specifically, 
the challenges and solutions identified in Section II will be mapped into requirements for 
a software solution.  These requirements will be used in Section VII, where an SOA-
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based solution using SOMA will be described.  The third and last part contains two 
sections in conclusion.  Section VIII contains an evaluation of the solution against the 
requirements of major stakeholders involved in the clinical trials process; and Section IX 
concludes with final thoughts. 
  
  
7 
 
II  Trust-Building in Clinical Research 
 
A. Challenges. 
According to Getz and Kremidas [5], the state of public relations in the clinical trials 
industry declined during the 5-year period of 1999 to 2004 due to the significant lack of 
education among the general public, prospective volunteer communities, medical and 
health professionals, and media.  The authors noted that most communications between 
clinical researchers and journalists focused on negative aspects of clinical trial execution 
or results.   
 
A survey of nearly 6000 adults [5] showed that 69% of them were aware of clinical trials 
through various media and that one in seven were exposed to information through their 
primary care or specialty care physicians.  However, less than 5% knew where to find 
information about relevant clinical trials.  A report of approximately 700,000 medical and 
health professionals active in community practices showed that less than half of them had 
referred a patient to a clinical trial, averaging to less than one patient referral per 
practitioner per year.   
 
Moreover, there was significant public distrust in clinical research, especially among 
adults in minority communities.  Surveys conducted in 1996, 2002, and 2006 [5] showed 
a decline of public trust in clinical research information from pharmaceutical companies.  
In 1996, 72% of those surveyed trusted clinical research information.  By 2006, this 
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percentage dropped to only 21%. 
   
Other studies in 2004 and 2006 showed public belief in the effectiveness of the FDA to 
ensure consumer safety had declined from 56% to 37% [6].  In a 2004 survey of more 
than 5,800 adults, 84% of the Latino respondents gave a response of “not very safe/not 
safe at all” to the question, “How safe do you think clinical research studies are for 
people who participate [5]?” 
 
Because of these types of issues, 90% of all clinical trials had to extend their timelines in 
order to enroll sufficient numbers of volunteers in a study.  To complete a trial, research 
sponsors had to spend increasingly more resources on patient recruitment, thus increasing 
trial costs.   
 
Research that is community-based brings additional challenges to trust-building, due to 
its collaborative nature and its need to understand and accommodate the language and 
culture of the community.  Trust must be established between outside researchers and key 
participants within the community, including community leaders, community-based 
partners, prospective study subjects, and healthcare providers.  Successful healthcare 
research involving socio-economically disadvantaged communities depends on the 
degree to which that research is “culturally appropriate and relevant to families in the 
communities where they live” [7]. 
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To establish successful trusting relationships with medical and healthcare professionals 
focused on the health of specific communities, a number of barriers must be overcome.  
Sometimes researchers may be perceived as outsiders who take data and define research 
priorities but do not give back to the community; or they may be perceived as drains to 
local resources.  In some cases, community members may be intimidated by the technical 
training of outside researchers; or they may be suspicious of the researchers’ motives.  If 
researchers only commit to a short-term partnership, it may be difficult to maintain trust 
[4], [7], [8]. 
 
There are also many potential barriers to establishing trust with prospective study 
subjects in these communities.  This includes lack of understanding of the clinical trials 
process, lack of informed consent, lack of researcher sensitivity to individual needs, loss 
of control by the subject, skepticism about the quality of care received, or opinions of 
trusted influencers.  When the research process is not thoroughly understood, subjects 
may not understand the difference between research and medical care.  Therefore, they 
may have unrealistic expectations of study participation.  They may also fear loss of 
medical records privacy.  Language and literacy issues may inhibit understanding of the 
research process or make informed consent more difficult, so prospective subjects may 
not fully understand the benefits and risks of participating in a study.  Subjects may feel a 
loss of control if they are not provided interim information about a study’s progress.  
They may be skeptical of the quality of care they will receive, due to different values and 
beliefs.  Furthermore, depending on the community culture, a potential subject’s trust 
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may be dependent on the views of family, friends, community leaders, and his or her 
healthcare providers [4], [7], [9]. 
   
Previous experiences in clinical trials can erode trust.  Potential subjects may have a 
sense of being over-researched but not helped.  Lack of follow-up by researchers from 
previous trials, lack of follow-through on various commitments, or awareness of 
historical mistreatment may significantly impact levels of trust.  A subject who 
participated in previous studies but did not see any benefits as a result of them is less 
likely to trust the clinical trials process.  If researchers do not conduct appropriate follow-
up during a trial or communicate study results, participants may become suspicious and 
less trustful [7], [8].    
 
As mentioned earlier, physicians and other healthcare providers can play a significant 
role in lowering trust barriers and influencing their patients’ decisions to participate in 
clinical trials.  Some of the reasons for the low rate of referrals by physicians are lack of 
awareness or understanding of the clinical trials process, fear of loss of patient control, 
and concerns about the resource or time demands associated with trial participation.  
Healthcare providers may not understand the importance of clinical research or the 
potential benefits and risks associated with participation.  If they do not have access to 
their patient’s study data, they may not feel sufficiently informed to continue to 
adequately treat their patients; or they may fear they will lose their patients after the study 
is completed.  They may also be reluctant to take on additional administrative work; or 
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they may have competing demands for their time [4], [6], [9]. 
 
List and Sempeera [7] also include an observation about the lingering effects from prior 
participation in community-based research.  If a community had a negative experience 
from a previous study, it was less likely to participate in another study, even if the two 
studies were completely unrelated.  This means that inconsistency in approach from study 
to study may impact levels of participation in future studies. 
 
When there is lack of trust between clinical researchers and local communities, 
researchers may not be able to enroll a sufficient number of active participants into a 
clinical trial, those who do enroll may not continue to participate for the duration of the 
study, or the data provided by trial subjects may not be complete or truthful.  For a 
clinical trial to be successful in traditionally underserved communities researchers must 
collaborate with the community to address local problems in a meaningful and impactful 
way; and trust-building must be incorporated throughout the clinical trials process.  
 
B. Solutions:  An Industry Perspective. 
The clinical trials process can be divided into planning, execution, and outcome stages.  
Actions to build and maintain trust can be incorporated into each of these stages, focusing 
on the specific needs of different types of community members, such as community-
based partners, community leaders, prospective trial subjects, and trial subject influencers 
such as their healthcare providers, friends, and family.  In addition, broad actions can be 
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taken, independent of any particular clinical trial, to increase understanding and literacy 
of the clinical trials process among the general public.  More details about these actions 
are described in following sections.  
 
 1) Trial Planning Actions:  During the research planning stage, researchers should 
involve the entire community in discussions on the local needs, issues, and concerns to 
ensure that the study is relevant and will be supported by the community.    These needs 
should be used to establish research priorities [6], [7], [8].  Community members should 
also be engaged to act as research consumer advocates and be given the opportunity to 
contribute to trial design and to ensure that the patient perspective is incorporated into the 
process [6]. 
 
Researchers should work with community members to design the trial with culturally 
appropriate questions, translations, and interactions [7].  This includes collaborating with 
partners and leaders to ensure informed consent [6], [7]. 
 
Informed consent, a key interaction required in clinical research, is a procedure to ensure 
that trial subjects understand the nature of the proposed treatment, possible alternatives, 
and potential risks and benefits.  Informed consent is a major issue in patient recruitment 
and retention; and it is even more important in community-based research, as it can be a 
way to empower participants in the decision-making process, thus engendering greater 
trust.  Eliciting input from community members during the research planning stage can 
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make the informed consent process more effective. 
 
To promote greater understanding and awareness of the clinical trials process, research 
consumer advocates should be engaged to educate prospective trial subjects about clinical 
trials.  These research consumer advocates would include community-based partners, 
leaders, and influencers.  In addition, community physicians and other healthcare 
providers should be engaged to talk to their patients about relevant trials and to identify 
and refer eligible patients.  Community members who had participated in earlier phases 
of the clinical trial or who were, themselves, in the pool of eligible trial candidates could 
be trained to act as influencers to encourage trial participation [5], [6], [7].    
 
To encourage greater power sharing and control, community members should be included 
on the research boards.  This would give community representatives more say in how 
funds are distributed [6], [7], [8].  Other ways to share power and control might be to 
recruit community partners and physicians as study investigators or to utilize their 
facilities as part of the study [6]. 
 
 2) Trial Execution Actions:  During the trial execution stage, trust can be maintained by 
continuing to share power and control with the community.  This should include 
community members as research consumer advocates who participate in trial monitoring.  
Other activities might include participating on data safety monitoring boards or gathering, 
analyzing, and disseminating trial information [6], [8]. 
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Another way to empower the community would be to ensure frequent communication 
between researchers and the community.  Primary and secondary physicians should 
continue to be informed of their patients’ progress during the trial.  Establishing two-way 
communication between physicians and researchers could eliminate feelings physicians 
might have of loss of control over their patients.  Trial participants should also be 
continually informed of progress, status, and trial results so they can make informed 
decisions about their continued participation.  Participants should have a way to 
communicate concerns or ask questions; and researchers should be responsive.  Ongoing 
communication to the community-at-large during the trial would demonstrate concern for 
the community [6], [7].  
 
Other ways to demonstrate concern for the community would be to provide health 
education to trial subjects, to continue use of culturally appropriate questions and 
translations, and to be sensitive to cultural values and beliefs when interacting with trial 
subjects [7].  It is also critical that all commitments made by researchers to individuals 
are met. 
 
Trust between researchers and candidate trial subjects can be enhanced by using trusted 
research consumer advocates and community healthcare providers as intermediaries for 
trial recruitment [6], [7].  Trial execution processes should facilitate trial referrals from 
these advocates. 
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 3) Trial Outcome Actions:  When a trial is complete, researchers should work with 
community-based partners and leaders to determine the most effective ways to 
disseminate trial results to trial subjects and influencers to maintain trust [1]. 
 
 4) General Awareness Actions:  The Parkinson’s Disease Foundation (PDF) [6] suggests 
addressing the trust issue through greater public disclosure and transparency.  The goal 
would be to raise awareness of ongoing research and to improve clinical trials literacy.  
Pre-education could be used to counter the way the public was receiving information 
about clinical research.   
 
To this end, the foundation developed a public web site [10] with extensive information 
about current clinical studies.  The purpose was to integrate various study registries and 
to provide a one-stop shop for people with Parkinson’s Disease (PD).  Potential 
participants could view information about relevant research and requirements for 
participation, testimonials from other participants, and targeted Frequently Asked 
Questions (FAQs).  Although the web site met the requirement for public disclosure, it 
was not producing the desired result.  Because of this, PDF recommended additional 
actions to increase awareness of and education on clinical research through ongoing one-
on-one and community communications [6]. 
 
Getz and Kremidas [5] suggest that outreach and advocacy programs are an effective way 
to address education and trust issues.  Earlier programs were limited in scope and 
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duration, resulting in inconsistent messages or only short-term benefits.  Because of this, 
the authors suggest that these programs be more broadly adopted and implemented across 
the entire clinical research professional community and integrated with all clinical 
research activities.  The authors specifically recommend implementation of these types of 
communications: 1) educational materials for potential volunteers that address unique 
needs of each community; 2) broad outreach and advocacy to emphasize the important 
role of healthcare professionals in the clinical trial process and to educate the general 
public about the clinical trials process; 3) generation of messages that convey the 
important role that clinical research plays in improving public health and why it is so 
costly; and 4) acknowledgement and appreciation for community participation in clinical 
trials.  Targeted audiences would include the general public, health professionals, policy 
makers, prospective trial subjects and their friends and families, and the media. 
 
The proposed actions described above are consistent with the National Institute of 
Health’s (NIH’s) Roadmap for Medical Research [4], [11].  This roadmap provides 
funding mechanisms to assist communities in developing their own projects.  It includes 
seven major recommendations for improving trust between researchers and the 
community [4]:  
• Recommendation 1:  Establish grant criteria. 
• Recommendation 2:  Enhance network and infrastructure by funding mechanisms 
for grass-roots studies and providing linkages to community groups. 
• Recommendation 3:  Integrate medical research into primary healthcare. 
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• Recommendations 4 and 5:  Require certain criteria in study design. 
• Recommendation 6:  Provide access to information about clinical trials. 
• Recommendation 7:  Provide software to determine if a person meets clinical trial 
criteria. 
 
These NIH recommendations are consistent with those previously stated and can be used 
as additional input into the requirements for a software solution.  Establishing a common 
approach in the clinical trials process, common study design criteria, and software to 
support compliance to processes may improve consistency among various researchers 
conducting trials within a community.  Consequently, a community’s overall view of 
researchers and clinical trials may improve. 
 
C. Solutions:  A Community Perspective. 
The solutions identified above do not take into account the possibility that there may be 
several clinical trials being conducted in a community during the same time period.  
When there are multiple clinical trials focused on the same community but sponsored by 
different researchers, additional trust-building actions may be required.  For example, if 
the clinical trials process is inconsistent from sponsor to sponsor or if trials focused on 
the similar problems are offering different treatments, trial subject candidates may find it 
more difficult to determine which trials to participate in, if they choose to participate at 
all.  
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Providing a consistent approach across all clinical trials activity targeted at a community 
by adhering to the NIH recommendations can reduce inconsistencies and reinforce trust 
developed by previous researchers or other concurrent researchers.  Working through a 
single interface to a community, such as a community-based research organization, can 
shield prospective trial subjects from significant differences.  These community 
organizations can also serve as objective trusted advisors to guide community members 
to the most relevant trials.  
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III  Health in the San Jose Hispanic Community 
 
According to the National Alliance for Hispanic Health, obstacles to providing quality 
healthcare “…involve cultural misunderstandings and miscommunications with patient 
populations whose languages, experiences, and backgrounds differ from those of their 
providers” [12].  This section summarizes primary health issues in the Hispanic 
community and explores some cultural characteristics of the San Jose Hispanic 
community that may affect their trust in clinical researchers that are focused on these 
issues.  Next, a case study will be introduced that will be used to guide and evaluate the 
solution developed in Section VI and Section VII. 
 
A. Community Health Issues. 
Pfizer conducted a study on health data of specific populations in the United States [13], 
including Mexican-Americans, and published the results in 2004.  Because Mexican-
Americans were the largest subgroup of the San Jose Hispanic community (more than 
87% during the years 2006 to 2008), the results of the study are pertinent and 
summarized here [14].  
 
Health data on high blood pressure, cholesterol, diabetes, and obesity from 1998 to 2000 
were analyzed.  Mexican-Americans were less likely than non-Hispanic whites to have 
high blood pressure or high cholesterol.  However, they were more likely to have diabetes 
or be obese.  
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The data studied shows that the number of Mexican-Americans afflicted with high blood 
pressure grew during the study period.  In comparison to non-Hispanic whites, the study 
found that Mexican-Americans were less likely to be diagnosed and treated.  Of those 
receiving treatment, Mexican-Americans were less successful in their efforts to lower 
their blood pressure to recommended levels.  Mexican-Americans were also less likely to 
be screened, diagnosed, or treated for high cholesterol.  However, if treated, they were 
more successful in lowering their cholesterol to recommended levels. 
 
The report shows that diabetes is more common among Mexican-Americans.  Mexican-
American women had nearly twice the rate of diabetes than non-Hispanic white women.  
Mexican-American women were also more aware of diabetes; and a larger percentage of 
them received treatment. 
 
These three diseases are related to a person’s weight; and the study shows that 33% of 
Mexican-Americans were considered obese, with middle-aged Mexican-Americans 
having the highest rate at 38% [13].  Obesity may be due to food selection that is based 
on cultural preferences, so it is important to understand that culture when developing 
recommendations for treatment [14].  
 
B. Cultural Issues Affecting Healthcare. 
According to a survey conducted by the American Community Survey in 2008 [14], the 
San Jose Hispanic community comprised 31.5% of the population in San Jose, California, 
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of over 900,000.  Of the city’s population who were 5 years or older, 23.7% spoke 
Spanish at home and 11.6% felt they did not speak English well.  These significant 
percentages indicate that the language issues affecting trust, as described in Section II, 
must be considered when planning trust-building actions. 
 
In addition to language, the National Alliance for Hispanic Health [12] identifies three 
common cultural characteristics that can influence trust.  They include the importance of 
family, the need to show respect, and the value of personal relationships.  Hispanics 
frequently consult with other family members about their illnesses and are more likely to 
involve their family members in discussions and decisions about treatments.  It is also not 
unusual for family members to be asked to accompany a patient during medical visits so 
they can be involved in the discussions with the healthcare provider.   
 
In the Hispanic community, respect is demonstrated through “appropriate deferential 
behavior towards others based on age, sex, social position, economic status, and 
authority” [12].  Because of their status, education, and training, Hispanics tend to value 
the opinions and recommendations of their healthcare providers.  To avoid being 
disrespectful, Hispanic patients might not verbally disagree with their providers or 
express doubts. 
 
They also expect that their healthcare providers will show them respect in return.  This 
respect is demonstrated by the way the healthcare provider interacts with a patient.  For 
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example, asking direct questions about personal problems such as alcoholism or mental 
health can be embarrassing and might be perceived as being disrespectful.  Respect is 
also shown by listening carefully to patient concerns and responding to them [12]. 
 
Hispanics value personal relationships over institutional ones, so they rely on 
community-based organizations or clinics for their primary care.  They also display 
loyalty to their individual providers.  If a patient’s physician moves to a different 
healthcare facility, it is not unusual for that patient to move to the new facility to keep the 
same provider.  If a move is not possible, the patient might discontinue treatment 
completely. 
 
C. Case Study. 
Because obesity is a significant health issue in the Hispanic community, it will be the 
focus of the case study.  This is a hypothetical study based on an actual study conducted 
by Stanford University in 2007 and targeted at mothers of Mexican descent in San Jose 
[15]. 
 
A subject participating in the study must: 1) be a mother of Mexican descent; and 2) be 
the parent of a child between the ages of 3 and 4.9.  The trial data to be collected in this 
case study will include the study subject’s BMI, 24-hour dietary recalls, household food 
inventories, activity monitoring, household food security levels, and food purchase 
motives. 
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D. Implications for Trust-Building. 
“Over time, by respecting the patient's culture and showing personal interest, a health 
care provider can expect to win their confianza (trust)” [12].  If the solutions identified in 
Section II are implemented, most of the trust influencers specific to the Hispanic 
community will be addressed.  Using culturally appropriate questions and translations can 
address language barriers and the need to demonstrate respect through tactful 
questioning.  Recruiting community members as patient advocates addresses the need to 
have personal relationships with researchers.  Encouraging more physician referrals may 
yield higher recruitment rates due to the loyalty and trust given to physicians by their 
Hispanic patients.  Ensuring general awareness in the community is a way to engage 
family members and other decision influencers.  Providing interim trial data to subjects 
and giving them the opportunity to ask questions and get feedback empower the subjects 
and demonstrate respect.  Because trust issues specifically associated with the Hispanic 
community can be addressed by the actions identified in Section II, no additional ones are 
required here. 
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IV  Software Tools for Managing Clinical Trials 
 
A. Commercial Software. 
To successfully manage a clinical trial, general-purpose or specialized software is used 
for trial planning, monitoring, management, execution, and administration.  Clinical trial 
management systems (CTMSs) focus on trial management, while clinical data 
management systems (CDMSs) focus on the data associated with the clinical trial.  
During the earlier phases of a clinical trial, internally developed software or general-
purpose software, such as spreadsheets, may be used.  Later, as the number of 
participants or tests increase, researchers may migrate to commercially available software 
to obtain richer functionality [16], [17].  They may also engage external contract research 
organizations (CROs) to manage trials on their behalf. 
 
Although all clinical trials have some function requirements in common, many have their 
own unique requirements [16].  This suggests that solution customization is an important 
feature required by clinical researchers.  They must be able integrate diverse software 
packages to manage the full scope of a clinical trial.  They also must be able to extend 
and adapt existing software to accommodate their unique needs.  Most existing software 
packages provide this adaptability through import/export techniques, use of code 
wrappers, or special purpose connectors.   Cancer Biomedical Informatics Grid Clinical 
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Trials Suite (caBIG1 CTS) [18] is a notable exception that is SOA-based, providing users 
greater flexibility. 
 
It should be noted that these existing software solutions focus on management of internal 
clinical trial processes.  With the exception of participant enrollment and management, 
there are few built-in features available in the software to support trust-building activities.  
 
B. Infrastructure Software. 
In 2004, the NIH Roadmap funded twelve (12) contracts [19]-[30] that focused on the 
development of an infrastructure of informatics, governance, and a common vocabulary 
to facilitate cooperation among research groups.  These contracts were part of the Clinical 
Research Networks and National Electronics Clinical Trials and Research Network 
(NECTAR) initiative.  Refer to Appendix C for a summary of the final reports.  Relevant 
results of these contracts are summarized below: 
 
The majority of projects developed systems focused on managing domain-specific data 
[19]-[28] or establishing common vocabularies for information interchange within 
existing networks [19]-[24], [30].  With the exception of CRN Harmony [25], these 
systems were custom-built applications rather than commercial off-the-shelf (COTS) 
ones.  The resulting solutions created tighter alignment between the IT infrastructure and 
                                                 
 
1
 caBIG is a registered trademark of the National Cancer Institute. 
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local processes and procedures; but they might not be transferrable to other clinical 
research organizations. 
 
The InterTrial project [26] suggests that “conventional software tools can help with some 
workflow problems…  However, these tasks tend to represent only a small part of a 
complex system…  There are also fundamental problems that cannot be solved with 
software alone.  In the community practice sites studied, clinical research and patient care 
are parallel but disconnected…”  This suggests that there needs to be a focus on tools that 
improve communications and infrastructure between clinical researchers and the 
community.   
 
Some projects were able to relate their results to changes in community interactions or 
their ability to reach underserved populations.  The Michigan Clinical Research 
Collaboratory (MCRC) project [19] improved communication to primary care providers 
(PCP) through extensions to the prompt and reminder system.  The Health Maintenance 
Organization Research Network Coordinated Clinical Studies Network (HMORN CCSN) 
project [27] increased research participation by providing participating cardiologists 
greater access to research information.  The Electronic Primary Care Research Network 
(ePRN) project [24] considered its ePCRN Gateway to be particularly suitable for 
underserved areas by promoting greater communication and collaboration.  The system 
was being considered for use at Hispanic clinics in Los Angeles.  The Research Involving 
Outpatient Settings (RIOS) Net project [29] used community outreach that included 
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Spanish-speaking staff; but it is not clear if this was through networked systems or via 
face-to-face interactions. 
 
C. Web Sites. 
Currently, web sites are the primary software tool used by researchers to communicate 
clinical trial information to the general public.  Content on these sites can be from a 
single source; or they can be portals that consolidate information from multiple sources.  
The PDF web site [10] is an example of a portal site. 
 
D. Summary of Tools. 
In summary, progress has been made to develop common vocabularies or information 
models to support clinical research.  Web sites are used to provide information about 
clinical research.  Some solution developers are creating features to improve 
communication among trial participants and provide easier access to research 
information.  However, the closed nature of the software architectures used by most 
commercial vendors and researchers makes it difficult to customize or extend existing 
solutions to support trust-building activity, leaving a high priority need unmet.  
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V  Introduction to SOA and SOMA  
 
In this section, key concepts of Service-Oriented Architecture (SOA) will be described 
along with the benefits of using SOA within an enterprise.  Next, the high-level steps of 
Service-Oriented Modeling and Architecture (SOMA) will be covered.  Finally, the 
applicability of SOA and SOMA to the issue of trust-building in the clinical research 
process will be explored. 
 
A. Service-Oriented Architecture. 
SOA is “an architectural style that supports service orientation.  Service orientation is a 
way of thinking in terms of services and service-based development and the outcomes of 
services” [31].  It is focused on the construction of services that are aligned with business 
concerns and can be combined to perform business processes within the context of an 
enterprise [32].  These services may be developed internally or externally.  They may be 
shared, distributed, and reused across multiple organizations within an enterprise. 
 
There are many definitions of SOA, some of which are conflicting [33].  However, there 
are some ideas that all SOA definitions have in common, such as the concept of a service 
and service composition, a services registry that provides information about available 
services, and governance to manage creation and use of services.  
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A service produces well-defined outcomes that are defined in a service contract.  Service 
providers perform the necessary actions to produce the outcomes; and service consumers 
use those outcomes.  Each service can stand alone, can be combined with other services, 
or can be composed of other services.  The actual service implementation is not visible to 
consumers or other services that incorporate it.  The services contract specifies how the 
service provider and service consumer will interact. 
 
A services registry is a mechanism for service providers to publish information about 
available services to potential consumers.  The registry typically contains details such as 
services descriptions and policies. 
 
SOA governance is concerned with the service life cycle and “focuses on the methods 
and processes around service identification, funding, ownership, design, implementation, 
deployment, reuse, discovery, access, monitoring, management, and retirement” [34]. 
 
One aspect that differentiates SOA from enterprise architecture (EA) is its emphasis on 
aligning an enterprise’s business processes with its information technology (IT).  A well-
defined SOA establishes linkages from enterprise goals and business processes to 
services.  As goals or business processes change, SOA facilitates service reuse.  The 
loose coupling of services within an SOA provides IT organizations greater agility and 
flexibility to meet enterprise needs. 
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Figure 1 depicts an SOA reference architecture, showing the various layers of building 
blocks and how they relate to each other. 
 
 
Figure 1. High-level view of an SOA reference architecture. 
 
Starting from the bottom layer in Figure 1 and moving up, the operational systems layer 
contains applications, infrastructure programs, and data that exist within the enterprise.  
These are basic building blocks that are used to develop services.  The service 
components layer contains other programs that are used as intermediaries to decouple 
services from the operational systems.  For example, this layer would include program 
wrappers to make operational systems available for use by systems.  The services layer 
contains services, services contracts, data used by services, and composite services.  The 
business processes layer contains business processes and information used by business 
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processes.  Last, the consumer layer contains users of the system and programs that 
interface to services [31]. 
 
Immediately to the right of the services building blocks in Figure 1 and continuing to 
move to the right, the integration layer enables the building blocks to communicate with 
each other.  The Quality of Service (QoS) layer is concerned with monitoring and 
managing issues such as performance, security, and manageability.  The information 
layer contains building blocks for transforming and managing data.  Last, the governance 
layer contains rules and procedures for implementation and operational governance [31]. 
 
B. Why Use an SOA Approach. 
A number of different architectural approaches were evaluated:  1) an entirely new 
system could be developed; 2) existing systems could be extended; or 3) an architecture 
could be developed that integrated new functionality with existing systems. 
 
An ideal framework for architecting a software solution that supports trust-building 
capabilities is one that lets the architect address key requirements for the solution, 
including the following: 
• The system must be integrated with existing systems that are used by an 
enterprise to manage clinical trials.  This includes general-purpose software, 
home-grown applications, or specialized CTMSs and CDMSs.  Duplicate data and 
function overlap should be minimized. 
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• The system must accommodate multiple CTMS and CDMS back-ends, since 
communities may be involved in more than one clinical trial at any given time. 
• The system must be sufficiently flexible to accommodate the specific 
requirements of each supported clinical trial.  Trials may use different software 
tools, have different types of stakeholders involved, or require different trust-
building actions.  Support for community-based research may have to 
accommodate unique cultural, language, or interface requirements. 
• The system must support rapid deployment and be cost-effective.    
 
Using an SOA will address these needs.  The benefits include the following:  1) the use of 
a service approach and loose coupling will enable easier integration with other systems; 
2) the use of service composition allows the system to be customized and extended; 3) 
specific needs of a given community can be addressed through tailored front-end 
applications accessing common back-end services; 4) the ability to share development 
and maintenance of the services means lower costs for information interchange; and 5) 
the system will be transferable and reusable among a greater number of research 
organizations. 
 
C. Service-Oriented Modeling and Architecture. 
There are several published methodologies for defining an SOA.  The Service-Oriented 
Modeling Framework (SOMF) and SOMA were evaluated for use in this study.  SOMF 
takes a service-first approach to discover and analyze service opportunities [35].  SOMA, 
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on the other hand, supports both operation-first and service-first approaches. Since it was 
anticipated that this solution would require development of new business processes, using 
SOMA with an operation-first approach was deemed more appropriate. 
 
In 2004, IBM2 announced SOMA as a methodology for identifying, specifying, realizing, 
and implementing services, components, and their flows [35].  At that time, SOMA was 
integrated with Global Services (GS) Method, a proprietary methodology.  In 2006, 
SOMA was integrated with IBM2 Rational Unified Process2 (RUP2), a commercially 
available product.  RUP is a flexible tool that allows an organization to define and 
customize its processes.  For example, it provides tailoring guidance on why certain 
outputs are needed and when they can be omitted.  As part of the integration effort, 
SOMA tasks were modified to be more consistent with RUP.   
 
Most recently, RUP has been subsumed by IBM Rational Method Composer3 (hereafter 
referred to as Method Composer), another commercially available product that is Eclipse-
based.  Method Composer provides process descriptions, work breakdown structures that 
identify required activities and tasks, artifact templates for work products, and guidelines 
for usage.  Support for SOMA is provided in RUP for SOMA (RUP/SOMA) Version 4.2, 
a plug-in for Method Composer.  There are some differences between RUP/SOMA and 
                                                 
 
2
 IBM, Rational, Rational Unified Process, and RUP are trademarks or registered trademarks of 
International Business Machines Corporation in the United States, other countries, or both. 
3
 Method Composer is a trademark or registered trademark of International Business Machines Corporation 
in the United States, other countries, or both. 
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SOMA methodologies.  These differences are noted in Appendix D.   
 
RUP/SOMA consists of three phases: 1) service identification; 2) service specification; 
and 3) service realization.  The purpose of service identification is to identify an initial set 
of services that are aligned to business goals.  Service identification can be performed 
operation-first or service-first.  In the operation-first approach, business processes are 
modeled; and services are derived from those models.  In the service-first approach, 
classes and components are identified.  Then operations are identified and added to the 
classes.  Services are identified through domain analysis [36]. 
 
Service identification consists of three major tasks:  1) domain decomposition; 2) goal 
service modeling; and 3) existing asset analysis.  The output from this phase is an initial 
Service Model.   
 
During the service specification phase, the structure of the service architecture is 
developed and refined; and the Service Model is developed further.  The Service Model 
provides the external view of a particular service, such as its expected outcomes, how to 
request the service, its dependencies, its service composition, and its messages.  The goal 
of this model is to design loosely coupled services that enable reuse [34]. 
 
The service realization phase focuses on an internal view of a service by using the Design 
Model.  This model represents how a service will be realized [34]. 
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A model resulting from a particular phase of RUP/SOMA can be traced to models in the 
next or previous phase, thus providing traceability from the business processes to each 
service.  Refer to Appendix E for more information about the content of the Service 
Model and the Design Model. 
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VI  Translating Needs to Software Requirements 
 
Abstract needs such as trust and the solutions for building trust as described in Section II 
are not specific enough to be able to derive a software functional specification.  Before a 
system can be architected, these high-level needs and the actions to address them must be 
synthesized and refined to identify an implementable set of software requirements and to 
ensure that the system does, in fact, address the original needs. 
 
In this section an approach to translate needs into software requirements will be 
demonstrated.  This approach consists of five steps: 
• Problem Analysis - Needs are analyzed and grouped into common themes. 
• Solution Analysis – Suggested actions are mapped against problem themes; and 
candidates for implementation via a software system are identified.  Risk analysis 
is performed against the candidates to understand which actions are most likely to 
yield the most benefit and also to understand which actions carry the most risk to 
implement. 
• Solution Mapping – Selected actions are mapped to existing business use cases; 
and candidates for implementation are further refined. 
• System Conceptualization – A high-level external view of a proposed system is 
defined.  This view is used to define technical requirements via requirements 
analysis. 
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These steps and their relationship to a typical software development lifecycle are 
illustrated in Figure 2. 
 
 
Figure 2. Approach to map needs to requirements. 
 
A. Problem Analysis. 
Needs are elicited from domain experts and are usually expressed in an unstructured 
manner and may be described in terms of problems to be solved.  These descriptions may 
be different facets of the same set of core problems, so the purpose of this first step is to 
aggregate the problems into common problem themes.   Table 1 shows the results of 
aggregating the challenges associated with trust that were identified in Section II.  Note 
that each problem theme is given a unique number to permit traceability later. 
 
Table 1. Results of Problem Analysis. 
Problem Theme Problem 
T-1. Previous encounters • Previous researchers did not follow through on 
commitments. 
• There is inadequate follow-up. 
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T-2. Lack of understanding of 
the research process 
• The research process is not thoroughly explained. 
• Candidate trial subjects misunderstand the difference 
between research and medical care. 
• Candidate trial subjects fear loss of medical records 
privacy. 
T-3. Ineffective informed 
consent 
• Informed consent cannot be adequately performed due to 
illiteracy or differences in language. 
T-4. Research relevancy • Research is not sensitive to candidate subject needs. 
• Research disregards the perspective of the community and 
their needs and priorities. 
T-5. Loss of power/control • No interim information is provided about study progress, 
so candidate trial subjects cannot make informed 
decisions. 
• The community cannot determine how data should be 
collected or used. 
T-6. Quality of care • Candidate trial subjects are skeptical of the quality of care 
they will receive. 
• Treatments may not be consistent with trial subject values 
or beliefs. 
T-7. Lack of commitment to 
community 
• People may feel over-researched.  They are sought out for 
research but get limited access to healthcare. 
• There is inadequate follow-up.  Researcher commitment 
is only for the duration of the study. 
• Researchers are perceived as taking data without any give 
back. 
T-8. Opinion of others • Candidate trial subjects may be aware of historical 
mistreatment during clinical trials. 
• Candidate trial subjects are affected by attitudes of family 
and friends. 
• Candidate trial subjects may be unwilling to go against 
their personal physicians' wishes. 
 
 
In Section II, it was noted that clinical trial referral rates by physicians have been low.  
Because candidate trial subjects value and trust the guidance of their personal physicians 
and healthcare providers, problems associated with engaging these professionals should 
be considered when defining possible solutions for building trust between candidate trial 
subjects and researchers. 
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Additional problem themes associated with physician referrals are identified in Table 2.  
Note that some of the themes are repeated from Table 1. 
 
Table 2. Themes Associated with Physician Referrals. 
Problem Theme Problem 
T-5. Loss of power/control • Physicians fear their patients won't return after they are 
referred. 
• Referring physicians receive no feedback about the outcome 
and/or status of their patients. 
T-9. Lack of awareness or 
understanding 
• Physicians are not aware of trials that are available to their 
patients. 
• Physicians do not understand the potential benefits and risks 
to their patients of participating in clinical trials. 
• Physicians lack awareness of clinical research and why it is 
important. 
T-10. Resource/time 
demands 
• Physicians often have competing demands and concerns. 
• Physicians are concerned about the administrative burden 
associated with patient participation. 
 
 
Additional problem themes can be derived by analyzing the trust-building solutions from 
a community perspective, as described in Section II.C.  These problem themes are 
identified in Table 3. 
 
Table 3. Themes from a Community Perspective. 
Problem Theme Problem 
T-11. Inconsistent processes 
and interfaces 
• The clinical trials process is inconsistent across trials 
being conducted in the community. 
• There are multiple interfaces between candidate trial 
subjects and researchers. 
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B. Solution Analysis. 
During this step, suggested actions are identified through techniques such as 
brainstorming and then are mapped against the problem themes identified in the previous 
step to ensure that all themes have been addressed.  If an action is mapped to a problem 
theme, it is considered to be a solution to that problem.  As with problem themes, each 
suggested action is given a unique number to permit traceability.   
 
Figure 3 illustrates the mapping between problem themes and suggested actions.  Note 
that there is a many-to-many relationship between the themes and actions, as shown for 
problem theme T-1 and action A-1. 
 
Table 4 shows the initial results in a tabular format.  Because the actions suggested in 
Section II are based on trial stages, the table is divided into subsections corresponding to 
each stage.  Review of the table shows that all problem themes have been addressed. 
 
Note that the NIH recommendations and solutions from a community perspective have 
not been mapped to themes.  This is because they are general policy statements and 
cannot be mapped to specific trust issues. 
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Figure 3. Mapping between problem themes and suggested actions. 
 
Table 4. Results of Solution Analysis. 
Trial 
Stage 
Problem Theme Suggested Action (Solution) 
Pre-
Planning 
T-1. Previous 
encounters 
A-1. Increase awareness about clinical research and the 
clinical trials process through education, outreach, and 
advocacy. T-2. Lack of 
understanding of 
the research process 
T-7. Lack of 
commitment to 
community 
T-8. Opinion of 
others 
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T-9. Lack of 
awareness or 
understanding 
A-2. Educate physicians on the benefits to their patients 
and themselves of participating in clinical trials. 
Planning T-1. Previous 
encounters 
A-3. Incorporate a community perspective in the clinical 
trials process. 
T-2. Lack of 
understanding of 
the research process 
A-4. Build community awareness of researcher presence; 
provide clinical trials education that is culturally 
appropriate. 
T-3. Ineffective 
informed consent 
A-5. Use culturally appropriate questions and translations 
to ensure comprehension and accessibility of informed 
consent. 
T-4. Research 
relevancy 
A-6. Incorporate community needs, patient perspectives, 
priorities, issues, and concerns in trial design. 
T-5. Loss of 
power/control 
A-7. Include members of the community in all stages of 
the clinical trials process for input, monitoring, and 
decision-making.  This includes participation on review 
boards and data safety monitoring boards. 
T-7. Lack of 
commitment to 
community 
A-6. Incorporate community needs, patient perspectives, 
priorities, issues, and concerns in trial design. 
T-8. Opinion of 
others 
A-8. Engage and train research advocates to participate in 
all stages of the clinical trials process, including subject 
recruitment.  
T-10. 
Resource/time 
demands 
A-9. Engage community physicians and healthcare 
providers as study investigators or by utilizing their 
facilities. 
Execution T-1. Previous 
encounters 
A-10. Ensure follow-through on commitments to trial 
subjects. 
T-2. Lack of 
understanding of 
the research process 
A-11. Ensure ongoing one-on-one communication with 
trial participants throughout the trial and be responsive to 
concerns. 
T-3. Ineffective 
informed consent 
A-5. Use culturally appropriate questions and translations 
to ensure comprehension and accessibility of informed 
consent. 
T-5. Loss of 
power/control 
A-11. Ensure ongoing one-on-one communication with 
trial participants throughout the trial and be responsive to 
concerns. 
A-7. Include members of the community in all stages of 
the clinical trials process for input, monitoring, and 
decision-making.  This includes participation on review 
boards and data safety monitoring boards as well as 
involvement in gathering, analyzing, and disseminating 
information. 
T-6. Quality of care A-12. Provide health education to trial subjects that is 
sensitive to cultural values and beliefs. 
T-7. Lack of 
commitment to 
A-12. Provide health education to trial subjects that is 
sensitive to cultural values and beliefs. 
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community A-11. Ensure ongoing communication to the community-
at-large throughout the trial. 
T-8. Opinion of 
others  
A-8. Engage and train research advocates to participate in 
all stages of the clinical trials process, including subject 
recruitment.  
T-11. Inconsistent 
processes and 
interfaces 
A-13. Provide a single consistent interface between the 
community and different researchers.  
Outcome T-7. Lack of 
commitment to 
community 
A-14. Disseminate project outcomes. 
 
 
C. Solution Mapping. 
Next, the actions or solutions defined in the previous step are mapped to existing business 
processes.  Mapping an action to a business process implies that the business process will 
incorporate that action.  If an appropriate existing business process cannot be identified 
for an action, a new business process must be created.   
 
This study will use a business architecture model for clinical trials that has been 
developed by caBIG [37] to identify existing business processes.  Table 5 shows the 
mapping and indicates if a new process must be defined or if an existing one must be 
modified.  
  
Table 5. Mapping Proposed Solutions to Business Processes. 
Solution Add or Modify Process Business Process 
A-1. Increase awareness about clinical 
research and the clinical trials process 
through education, outreach, and advocacy. 
Add a community outreach 
process.  Target media, 
policy makers, healthcare 
providers, and the 
community-at-large. 
Perform Outreach 
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A-2. Educate physicians on the benefits to 
their patients and themselves of 
participating in clinical trials. 
Add a community outreach 
process.  Target media, 
policy makers, healthcare 
providers, and the 
community-at-large. 
Perform Outreach 
A-3. Incorporate a community perspective 
in clinical trials process. 
Modify processes per other 
business requirements. 
All existing 
business 
processes, where 
appropriate 
A-4. Build community awareness of 
researcher presence; provide clinical trials 
education that is culturally appropriate. 
Add a community outreach 
process.  Target media, 
policy makers, healthcare 
providers, and the 
community-at-large. 
Perform Outreach 
A-5. Use culturally appropriate questions 
and translations to ensure comprehension 
and accessibility of informed consent. 
Modify Plan Study and 
Initiate Study processes to 
incorporate tasks to make 
them more culturally 
appropriate. 
All informed 
consent processes 
A-6. Incorporate community needs, patient 
perspectives, priorities, issues, and 
concerns in trial design. 
Modify Plan Study 
processes to include input 
from community members. 
All existing 
business 
processes, where 
appropriate 
A-7. Include members of the community in 
all stages of the clinical trials process for 
input, monitoring, and decision-making.  
This includes participation on review 
boards and data safety monitoring boards. 
Modify Plan Study 
processes to include 
participation by community 
members. 
All existing 
business 
processes, where 
appropriate 
A-8. Engage and train research advocates 
to participate in all stages of the clinical 
trials process, including subject 
recruitment. 
Add new business processes 
to manage patient advocate 
recruitment, training, and 
registration. 
Manage Patient 
Advocates 
 
Add a new business process 
to register a patient advocate 
for a trial. 
Register Patient 
Advocate 
Add a new business process 
for referral from the 
Enrolling Physician. 
Refer Subject 
A-9. Engage community physicians and 
healthcare providers as study investigators 
or by utilizing their facilities. 
Modify Plan Study 
processes to include 
consideration of community 
members. 
All existing 
business 
processes, where 
appropriate 
A-10. Ensure follow-through on 
commitments to trial subjects. 
not applicable not applicable 
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A-11. Ensure ongoing one-on-one 
communication with trial participants 
throughout the trial and be responsive to 
concerns. 
Add a new business process 
to permit monitoring and 
Q&A by study subjects and 
their enrolling physicians. 
Monitor Study 
Obtain Trial Data 
A-12. Provide health education to trial 
subjects that is sensitive to cultural values 
and beliefs. 
 
Add a new business process 
to provide health education 
during a clinical trial. 
Provide Health 
Education 
A-13. Provide a single consistent interface 
between the community and different 
researchers. 
not applicable not applicable 
A-14. Disseminate project outcomes. Add a new business process 
to communicate outcomes to 
the community. 
Disseminate Trial 
Results 
 
 
In most cases, trust-building activities can be incorporated into the model by updating 
existing business processes.  However, some new business processes are needed to define 
interactions with the community.  Also, two new business processes, Perform Outreach 
and Manage Post-Study, have been identified to manage activities before and after 
clinical trials, respectively.  The Business Process column shows “not applicable” if the 
corresponding business requirement describes an action that is more effectively 
implemented through some means other than a business process. 
 
D. System Conceptualization. 
A view of the new business processes and their relationships to existing ones is then 
developed.  The results are shown in Figure 4.  Manage Community is shown as a 
separate group of new business processes that manages interactions between the 
community and clinical trials personnel.  This approach shields the community from 
differences in business processes used by various researchers who may be operating 
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within the community and from different clinical trial systems used for managing trials of 
interest.   
 
The roles on the left side of the figure correspond to major actors involved in the 
processes.  The boxes on the right represent systems used by clinical trials personnel.  
The arrows represent the flow of information between actors, processes, and systems. 
 
 
Figure 4. Interaction between new and existing business processes. 
 
E. Requirements Analysis. 
Using the external view defined in the previous step, more detailed technical 
requirements can be developed.  Requirements for each of the processes are shown in 
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Table 6.  Requirements have not been specified for Perform Outreach or Provide Health 
Education because they will be specific to the implementing organization. 
 
Table 6. Manage Community Requirements. 
Req ID Description 
CR1 The system shall support the Manage Community process. 
CR1.1 The system shall support the Manage Patient Advocates process 
CR1.1.1 The Manage Patient Advocates subsystem shall provide a way for a 
community research coordinator to create, retrieve, update, or delete (CRUD) 
contact information about patient advocates and enrolling healthcare 
providers within the community. 
CR1.1.2 The Manage Patient Advocates subsystem shall provide a way to register a 
patient advocate for a particular clinical trial. 
CR1.2 The system shall support the Refer Subject process 
CR1.2.1 The Refer Subject subsystem shall provide shall provide information about 
clinical trials being conducted in the community. 
CR1.2.1.10 The Refer Subject subsystem shall provide a list of clinical trials that are 
currently seeking participants. 
CR1.2.1.20 The Refer Subject subsystem shall provide a description of a selected active 
clinical trial. 
CR1.2.1.30 The Refer Subject subsystem shall list eligibility requirements for a selected 
active clinical trial. 
CR1.2.1.40 The Refer Subject subsystem shall provide information about benefits and 
risks of participating in a selected active clinical trial. 
CR1.2.2 The Refer Subject subsystem shall provide a way for a patient advocate or 
enrolling physician to refer a subject to a trial. 
CR1.2.2.10 The Refer Subject subsystem shall provide a way to list all candidates 
associated with a patient advocate and the status of each candidate. 
CR1.2.2.20 The Refer Subject subsystem shall provide a way to create, retrieve, update, 
or delete (CRUD) information about a candidate subject. 
CR1.2.2.30 The Refer Subject subsystem shall provide a way to submit a candidate for 
consideration. 
CR1.2.2.40 The Refer Subject subsystem shall provide a way to link each candidate to 
the enrolling patient advocate or physician. 
CR1.2.3 The Refer Subject subsystem shall provide a way to register candidates for an 
active trial. 
CR1.2.3.10 The Refer Subject subsystem shall provide a way for a site registrar to 
review all candidates for a trial. 
CR1.2.3.20 The Refer Subject subsystem shall provide a way for a site registrar to 
determine if the candidate meets eligibility requirements. 
CR1.2.3.30 The Refer Subject subsystem shall provide a way for a site registrar to 
register a selected candidate for a trial. 
CR1.3 The system shall support the Monitor Subject process 
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CR1.3.1 The Monitor Subject subsystem shall provide a way for a trial subject to 
monitor his or her progress during a trial. 
CR1.3.1.10 The Monitor Subject subsystem shall provide a way to request a report of 
the subject’s trial data. 
CR1.3.1.20 The Monitor Subject subsystem shall provide a report of a subject’s trial 
data. 
CR1.3.1.30 The Monitor Subject subsystem shall provide a way to submit an ad hoc 
question. 
CR1.3.1.40 The Monitor Subject subsystem shall provide a way to respond to an ad hoc 
question. 
CR1.3.2 The Monitor Subject subsystem shall provide a way for an enrolling 
healthcare provider to monitor a patient’s progress during a trial. 
CR1.3.2.10 The Monitor Subject subsystem shall provide a way to request a report of 
the subject’s trial data. 
CR1.3.2.20 The Monitor Subject subsystem shall provide a report of a selected subject’s 
trial data. 
CR1.3.2.30 The Monitor Subject subsystem shall provide a way to submit an ad hoc 
question. 
CR1.3.2.40 The Monitor Subject subsystem shall provide a way to respond to an ad hoc 
question. 
CR1.4 The system shall support the Monitor Trial Data process 
CR1.4.1 The Monitor Trial Data subsystem shall provide a way to request a report of 
the trial status. 
CR1.4.2 The Monitor Trial Data subsystem shall provide report of trial status. 
CR1.4.3 The Monitor Trial Data subsystem shall provide a way to submit an ad hoc 
question. 
CR1.4.4 The Monitor Trial Data subsystem shall provide a way to respond to an ad 
hoc question. 
CR.1.5 The system shall support the Disseminate Trial Results process. 
CR1.5.1 The Disseminate Trial Results process shall provide a way to request a report 
of trial results. 
CR1.5.2 The Disseminate Trial Results process shall provide a study results report. 
CR2 The system shall be accessible via the Internet. 
CR2.1 The system shall be accessible through standard browsers on Windows and Mac 
clients.  
CR2.2 The system shall be accessible through mobile devices. 
CR3 The system shall provide a secure environment. 
CR3.1 The system shall meet all applicable government regulations for privacy and 
security. 
CR3.2 The system shall support authentication and authorization. 
CR4 The system shall provide translated information, where appropriate, to ensure 
informed consent. 
CR5 The system shall support multiple, concurrent active trials. 
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VII  An SOA-Based Solution to Build Trust 
 
Now that technical requirements have been defined, the design phase of the software 
development lifecycle can begin.  During this phase, the architecture is developed. 
 
The RUP/SOMA methodology, as defined by IBM Rational Method Composer Version 
7.5.0.1 [36], will be used to architect and model a solution for increasing trust between 
the San Jose Hispanic community and clinical researchers.  It will be used as the basis for 
determining the process phases and activities to be followed.  Each task in the 
RUP/SOMA work breakdown structure corresponds to a subsection in this section.  If 
there are templates or alternative modeling notations defined in the original SOMA 
methodology, they will be given preference over RUP/SOMA.  Any deviations, such as 
modeling notations, from the RUP/SOMA methodology will be noted.   
 
Because most clinical trials use some form of information technology to manage their 
processes, the assumption of this study is that any new services must fit within the 
context of existing systems.  In 2008, the National Cancer Institute launched an 
information initiative to encourage collaboration among the cancer community.  To that 
end, they created the Cancer Biomedical Informatics Grid (caBIG) [38].  This initiative 
includes activity to architect and develop a clinical trials management system based on 
open standards, including SOA, to support cross-organization collaboration [39].  For this 
study, caBIG will be used as the basis for any enterprise-level modeling that must be 
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created as part of implementing the RUP/SOMA methodology. 
 
A. Service Identification. 
This is the first phase of RUP/SOMA.  During this phase, the Service Model and Goal-
Service Model are developed.  To ensure alignment of business processes to services, an 
operation-first approach will be used.  Service Identification consists of Domain 
Decomposition, Goal-service Modeling, and Existing Asset Analysis activities.  
 
 1) Domain Decomposition:  This activity is used to identify candidate services and 
associated service flows.  It is performed top-down to ensure that services that align with 
the business.  This step is also used to understand the relationships among different 
business functions within a business to identify commonalities where services may be 
shared.  Table 7 summarizes the tasks and their inputs and outputs. 
 
Table 7. Domain Decomposition Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Function area analysis Business Domain Business Analysis Model 
Business Architecture 
Document 
Refine a business use case Business Actor 
Business Use Case 
Business Use Case 
Model 
Business Actor 
Business Use Case 
Business Use Case Model 
Business process analysis Business Analysis Model Service Model 
Business use case analysis 
(SOA) 
Business Analysis Model 
Service Model 
Service Model 
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  a) Functional area analysis:  The purpose of this task is to partition a business into its 
functional areas and to understand the relationships among them.  The outputs are a 
Business Analysis Model and a Business Architecture Document.  The Business Analysis 
Model is an abstraction of the business and shows how business workers, business 
entities, and business systems interact to fulfill the goals of that business.  The Business 
Architecture Document provides a comprehensive view of the business and is used to 
describe the structure of the business, including its organizational structure and how 
responsibilities and business work are allocated within that structure. 
 
Per RUP/SOMA guidelines, if the objective of the project is to specify a needed behavior, 
a Business Analysis Model is not required.  The Business Architecture Document serves 
as the basis for making informed decisions about a project and does not directly affect the 
architecture of the information technology solution itself.  Because the project is focused 
on trust-building, a specific behavior, and is of interest to only one business function, 
these two work products will not be produced for this study. 
 
However, some general comments about business functions and the role that the clinical 
trials function plays within a business will be covered briefly here.  This information can 
be used when investigating opportunities for service reuse, either as a consumer or as a 
provider, and when deciding on service ownership. 
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If a business has public relations, communications, or marketing/sales functions, those 
functions may already be involved in activities associated with community outreach or 
with local physicians and other healthcare providers who are their customers.  If so, the 
systems they use should be explored to determine if there is potential for service reuse.  
For this study, the assumption is that no other functions within the business have systems 
that can be reused.   
 
The role of the clinical trials function within a business will depend on the purpose of that 
business.  For example, it would be a supporting function in a business that develops 
drugs or treatments for commercial use; whereas it would be the primary function in a 
research organization.  It would be the core business for a contract research organization 
that manages clinical trials on behalf of outside researchers.   Thus, the question of 
ownership must be decided on a specific case-by-case basis. 
   
Although RUP/SOMA is only focused on internal functional areas, it is also important to 
understand how the business interacts with external entities that are critical to the success 
of the business.  In the case of this study, volunteers for clinical trials and their 
communities perform a function that is vital to any business that requires clinical trials.  
Therefore, the business architecture should also consider the role of communities within 
their business. 
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  b) Refine a business use case:  The purpose of this task is to refine existing business use 
cases so they contain sufficient detail to be realized.  The outputs are Business Actor, 
Business Use Case, and Business Use Case Model for each refined business use case. 
 
Inputs to this task are Business Actor, Business Use Case, and Business Use Case Model.  
RUP/SOMA assumes these inputs were created at an earlier point in time; and it does not 
include tasks for creating them in the work breakdown structure.  The caBIG CTMS 
architecture model [37] defines business actors, business processes, and business use 
cases in sufficient detail to permit realization, so no additional work is required for this 
step.  Refer to Appendix G to see the subset of business use cases that are relevant to this 
study. 
 
  c) Business process analysis:  The purpose of this task is to analyze business processes 
to identify candidate services.  In this task, business processes are decomposed into more 
and more levels of detail until user interfaces start being considered.  The most detailed 
levels are considered leaf-level sub-processes and are candidates for services.  The output 
is an initial version of the Service Model where the service portfolio is identified and 
organized into a service hierarchy. 
 
This task should consider both existing and new business processes.  Refer to Appendix 
G to see the new business processes.  The initial analysis is shown in Figure 5, Figure 6, 
and Figure 7, using a SOMA notational form to show the relationship between business 
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processes and services.  Business processes and their flows are represented in the 
Business Aspect; and use cases are represented by bubbles in the IT Aspect.  Due to the 
large number of sub-processes in this domain, only new sub-processes are shown.  On an 
actual project, all sub-processes would be included in the analysis.  This would ensure 
that the relationships between the business and IT are maintained. 
 
Figure 5 shows the highest level of business processes.  Figure 6 shows the 
decomposition of the first three processes.  Figure 7 shows the decomposition of the last 
two processes.  RUP/SOMA states that the mapping between use cases and services are 
typically one-to-one.  Note that services have not been defined for Perform Outreach and 
Provide Health Education business processes because they are not expected to have 
significant IT requirements.  Obtain Trial Results does not appear because it is not 
specifically associated with a business process. 
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Figure 5. Top-level business processes. 
 
 
Figure 6. Sub-processes and use cases - Part 1. 
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Figure 7. Sub-processes and use cases - Part 2. 
 
Although not required by RUP/SOMA at this point, it is useful to repeat Step b) to refine 
the new business use cases so there is sufficient information for realization.  These are 
defined in Appendix H. 
 
After refinement of the new business use cases some changes have been identified: 
• Manage Patient Advocates has been decomposed into two business use cases, 
Recruit Patient Advocate and Train Patient Advocate.  A service will not be 
created for Train Patient Advocate, since implementation will have minimal IT 
requirements. 
• Refer Subject has been decomposed into three business use cases, Manage Trial 
Candidate, Request Subject Referral, and Manage Referral Request. 
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• Obtain Trial Data has been added to the Report and Analyze Study Category. 
 
RUP/SOMA uses a service hierarchy to organize services into a classification scheme.  
The caBIG classifications will be used to facilitate better integration with the caBIG 
architecture because they roughly approximate the different functions associated with 
clinical trials.  Figure 8 shows the service classification hierarchy for candidate services 
based on the results of business process analysis. 
 
 
Figure 8. Service Model: service hierarchy. 
 
RUP/SOMA provides a template for capturing information about services that will be 
used to support service identification and service specification.  During the service 
identification phase, the primary concerns are mapping services to business functions and 
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goals, identifying existing assets, and noting the status of the service.  Table 8 is a 
completed template for the services that have been identified in Figure 8.  At this point, 
all services are in candidate status, so all services have a status of “C.” 
 
Table 8. Service Model: Service Portfolio After Business Process Analysis. 
Service Description Status Associations 
Function / 
Process 
Goal Asset 
Recruit Patient 
Advocate 
Manage potential patient advocate. C Pre-Study   
Register Patient 
Advocate 
Register patient advocate as participant 
in clinical trial. 
C Initiate Study   
Manage Trial 
Candidate 
Manage potential subject, including 
information about him/her. 
C Conduct Study   
Request Subject 
Referral 
Request to register subject into a trial C Conduct Study   
Manage Referral 
Request 
Review request to register subject into 
a trial. 
C Conduct Study   
Monitor Subject Generate a view of trial data for a 
specified subject, submit questions, 
and review answers. 
C Conduct Study   
Monitor Trial 
Data 
Generate a view interim trial data. C Conduct Study   
Obtain Trial 
Data 
Query CDMS to retrieve data. C Report and 
Analyze Study 
  
Disseminate 
Trial Results 
Send a final report in a format that can 
be viewed. 
C Post-Study   
 
 
  d) Business use case analysis (SOA):  The purpose of this task is to review business use 
cases to identify and refine the candidate services.  Reviewing the set of operations for a 
business use case realization may reveal some services that are conversational in nature.  
In those cases, the architect should consider aggregating those services into a single one.  
The output is an updated Service Model.  After review of the business use cases, none 
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have been identified to be conversational.  As a result, no changes are required. 
 
 2) Goal-Service Modeling:  This activity is used to determine which services will help 
the business achieve desired goals and to identify where there may be a services gap.  
Metrics are defined to measure how well services perform against those business goals.  
A Goal-Service Model is created to map business goals to specific metrics and services.  
Table 9 summarizes the tasks and their inputs and outputs. 
 
Table 9. Goal-Service Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Identify business goals and KPIs Business Vision Business Goal 
Identify and associate services to goals Business Goal 
Service Model 
Goal-Service Model 
 
 
  a) Identify business goals and KPIs:  The purpose of this task is to identify the goals 
that are relevant to the project and to identify ways to measure the effectiveness of the 
services being developed to meet those goals.  The output is Business Goal, a hierarchical 
list of goals and one or more key performance indicators (KPIs) for each goal. 
 
As discussed in Section II, lack of trust between clinical researchers and the communities 
where they operate can impact the ability to recruit and retain subjects in clinical trials.  
This, in turn, affects the total cost of a clinical trial.  Figure 9 reflects this linkage. 
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Note that some goals do not have KPIs.  This is because it may be difficult to measure 
that specific goal.  In these cases, the KPI for a goal higher or lower in the hierarchy can 
serve as an indirect KPI.  Also note that this is not a strict hierarchy.  Goals 1.1.1, 1.2.1, 
and 2.2.1 are identical and show that implementing a single sub-goal can help an 
organization achieve multiple higher-level goals.  Finally, note that this is only a subset 
of goals that a business might have.  Only those that are relevant to the project are shown. 
 
The specific percentage improvements in goals 1, 1.2, and 2.2 should be determined by 
the sponsoring organization.  For this study, placeholders have been used. 
 
 
Figure 9. Business goal hierarchy.   
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Because these business processes focus on the interactions between researchers and the 
community, the services must also be effective in helping the community meet their 
goals.  Community goals are focused on improving the health of community members, as 
shown in Figure 10. 
 
 
Figure 10. Community goal hierarchy. 
 
  b) Identify and associate services to goals:  The purpose of this task is to link services to 
business goals.  The output is a Goal-Service Model in tabular form that maps the 
information from Business Goal in Figure 9 and Figure 10 to specific metrics and 
services, as shown in Table 10.  Note that services related to recruitment and patient 
referral are mapped to the community goal.  This is based on the assumption that 
participation in relevant clinical trials can result in effective treatment of health concerns. 
 
Table 10. Preliminary Goal-Service Model. 
Goal or Sub-Goal KPIs Metric Services 
1: Reduce clinical trial 
costs. 
Reduce clinical trial 
costs by w%. 
Record recruitment 
spending. 
 
1.1: Improve trial subject 
recruitment rates. 
 
X% increase in the 
number trials that 
successfully enroll 
the required number 
of eligible subjects 
within the planned 
recruitment period. 
Record planned 
enrollment time 
lines versus actual. 
 
Manage Trial 
Candidate 
Request Subject 
Referral 
Manage Referral 
Request 
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1.1.1: Increase trust 
between clinical 
researchers and the 
communities where they 
operate. 
Reflected in KPI for 
Goal 1.1. 
n/a Recruit Patient 
Advocate 
Register Patient 
Advocate 
 
1.2: Improve trial subject 
retention rates. 
Reduce drop-out rate 
by y%. 
 
Record status of 
each subject 
enrolled in a trial. 
Monitor Subject 
Monitor Trial Data 
1.2.1: Increase trust 
between clinical 
researchers and the 
communities where they 
operate. 
Reflected in KPI for 
Goal 1.2. 
n/a Obtain Trial Data 
Disseminate Trial 
Results 
2: Improve quality of 
trial data. 
Reflected in KPI for 
Goal 2.1. 
n/a  
2.1: Improve quality of 
data submitted by trial 
subjects. 
Reduce the number 
of trial data points 
that must be omitted 
from the study by 
z%. 
Record status of data 
points for a given 
trial subject. 
Recruit Patient 
Advocate 
Register Patient 
Advocate 
Monitor Subject 
2.1.1: Increase trust 
between clinical 
researchers and the 
communities where they 
operate. 
Reflected in KPI for 
Goal 2.1 
n/a Obtain Trial Data 
Disseminate Trial 
Results 
3: Receive effective 
treatment for a health 
concern. 
Medical condition is 
cured or successfully 
managed. 
Recorded as part of 
trial execution.  
Identified during 
trial planning. 
Recruit Patient 
Advocate 
Register Patient 
Advocate 
Manage Trial 
Candidate 
Request Subject 
Referral 
Manage Referral 
Request 
Monitor Subject 
Monitor Trial Data 
 
 
 3) Existing Asset Analysis:  This activity is used to identify existing assets.  Table 11 
summarizes the tasks and their inputs and outputs. 
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Table 11. Existing Asset Analysis Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Existing asset analysis Service Model Service Model 
Data model analysis Service Model Service Model 
Business rule analysis Service Model Service Model 
Construct Architectural Proof-of-Concept (SOA) Service Model  
 
 
  a) Existing asset analysis:  The purpose of this task is to review existing applications to 
identify candidate services for the solution.  For this task, the business application 
portfolio is examined to understand the functionality the applications provide.  This 
application portfolio includes custom applications and COTS.  A coarse-grained mapping 
of business functions to services is performed to identify candidate services from these 
applications.  The output is an updated Service Model. 
 
For this study, it is assumed that the caBIG systems are the only ones in the business that 
have relevant applications.  There are three caBIG systems that are used in this study.  
caBIG Clinical Trial Suite 2.0 (CTS) [18] is a services-based system for use at clinical 
trial sites.  caGrid 1.3 [40] is the underlying platform and infrastructure that integrates 
caBIG tools and provides common services such as authorization and authentication.  
caBIG Integration Hub [41] is a service bus that manages access to services provided by 
components of CTS.  The specific services that are available are documented at caBIG 
Knowledge Center [42]. 
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Based on this assumption, the Service Model has been updated with additional candidate 
services, Patient and Registration.  These are shown in bold type in Table 12.  Although 
not explicitly included in the RUP/SOMA methodology, the Goal column has been 
updated with goals from the goal hierarchies in Figure 10 and Figure 11, since that 
information is now available. 
 
Table 12. Service Model: Service Portfolio After Existing Asset Analysis. 
Service Description Status Associations 
Function / 
Process 
Goal Asset 
Recruit Patient 
Advocate 
Manage potential patient advocate. C Pre- Study 1.1.1 
2.1 
3 
 
Register Patient 
Advocate 
Register patient advocate as 
participant for a trial. 
C Initiate Study 1.1.1 
2.1 
3 
 
Manage Trial 
Candidate 
Manage potential subject, including 
information about him/her. 
C Conduct Study 1.1 
3 
 
Request Subject 
Referral 
Request to register subject into a trial C Conduct Study 1.1 
3 
 
Manage Referral 
Request 
Review request to register subject into 
a trial. 
C Conduct Study 1.1 
3 
 
Monitor Subject Generate a view of trial data for a 
specified subject, submit questions, 
and review answers. 
C Conduct Study 1.2 
2.1 
3 
 
Monitor Trial 
Data 
Generate a view interim trial data. C Conduct Study 1.2 
3 
 
Obtain Trial 
Data 
Generate a report of trial data or 
outcomes. 
C Report and 
Analyze Study 
1.2.1 
2.1.1 
 
Disseminate 
Trial Results 
Send a final report in a format that can 
be viewed. 
C Post-Study 1.2.1 
2.1.1 
 
Patient Manage and query patients. C Conduct 
Study 
1.2 CTS 
Registration Manage and query registration. C Conduct 
Study 
1.1 CTS 
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  b) Data model analysis:  The purpose of this task is to examine the business domain 
model to identify additional candidate services for the solution.  The domain model is 
examined for business entities that overlap with those of the solution domain.  By 
identifying the systems that operate on those entities within the business, one may find 
other applications that are candidates for services.  The output is an updated Service 
Model. 
 
Because this study assumes that CTS is the only system with relevant applications, no 
additional candidate services have been added. 
 
  c) Business rule analysis:  The purpose of this task is to examine the business rules to 
identify additional candidate services for the solution. 
 
Business rules are examined to determine if any can be externalized via a service.  
Externalizing these rules from the logic will allow the rules to evolve independently 
without affecting the application logic, thus removing variability.  The output is an 
updated Service Model. 
 
Trial eligibility criteria are business rules to determine if a prospective subject meets the 
requirements to participate in a clinical trial.  These criteria are unique to each clinical 
trial.  An application that automatically evaluates the eligibility of a prospective subject 
would be a candidate service.  However, at the time the study was conducted, CTS did 
  
66 
 
not have such an application or service, so there is no change to the Service Model. 
 
  d) Construct architectural proof-of-concept:  The purpose of this task is to develop a 
prototype of the architecture or a conceptual architecture to evaluate its feasibility.   
In the proof-of-concept, non-functional requirements, such as exception handling and 
data availability, are evaluated to determine if the proposed solution is feasible.  No 
output is defined for this task. 
 
A conceptual architecture is illustrated in Figure 11.  Access to web services will be 
through caBIG Integration Hub, which is an enterprise service bus based on open 
standards [41].  Exception handling and message conversions will be handled by caBIG 
Integration Hub.  Data associated with a trial will be in a separate CDMS.  caBIG 
Integration Hub can access these CDMSs through a Clinical Connector.  At the time of 
this study, four popular CDMSs were being evaluated for implementation.  This study 
assumes that a supported CDMS will be used for implementing the solution. 
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Figure 11. Conceptual architecture. 
 
B. Service Specification. 
This is the second phase of RUP/SOMA.  During this phase, the Service model is 
updated to document service exposure decisions, to identify interdependencies among 
services, and to define service messages.  The Design Model is developed to provide 
greater details about services and to describe the components of the solution and 
relationships among them.  Service Specification consists of Perform Service 
Specification, Perform Subsystem Analysis, and Perform Component Specification. 
 
 1) Perform Service Specification:  This activity is used to further specify the services. 
Table 13 summarizes the tasks and their inputs and outputs. 
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Table 13. Perform Service Specification Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Apply services litmus 
tests 
Service Model Goal-Service Model 
Service Model 
Service specification Service Model Service Model 
Message design Service Model Service Model 
Identify security patterns Software Architecture 
Document 
Software Architecture 
Document 
 
 
  a) Apply services litmus tests:  The purpose of this task is to select which of the 
candidate services are to be exposed.  The outputs are an updated Goal-Service Model 
and an updated Service Model. 
 
For this task, each candidate service is evaluated against a set of criteria: 
• Is the service aligned with the business? 
• Is the service composable?  For example, is the service stateless and is it self-
contained? Is it technology neutral? 
• Does the service have an external description?  This would be applied to existing 
applications. 
• Can this service be reused? 
• Is the service technically feasible? 
 
Candidates that do not meet all these criteria will not typically be exposed.  However, this 
evaluation is an iterative process, so the decision may change as more information about 
eliminated services is discovered.  Regardless, the eliminated services will still be 
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implemented in some manner, perhaps as applications on top of service components or as 
internal services. 
 
Table 14 maps each candidate service against the criteria.  Note that there are a number 
of services that will be exposed, even though they do not meet the external description 
criteria.  This is because these services have not been implemented yet and external 
descriptions do not exist.  While performing this task, it was noted that Register Subject 
duplicates an existing service, so this service will not be exposed at this time. 
 
Table 14. Service Model: Service Exposure Decision. 
Service Expose Service Litmus Test Results 
Aligned Composable External  
Description 
Reusable Feasible Comments 
Recruit Patient 
Advocate 
Y x x  x x new service 
Register 
Patient 
Advocate 
Y x x  x x new service 
Manage Trial 
Candidate 
Y x x  x x new service 
Request 
Subject 
Referral 
N x    x new service 
Manage 
Referral 
Request 
N x    x new service 
Monitor 
Subject 
N x    x new service 
Monitor Trial 
Data 
N x    x new service 
Obtain Trial 
Data 
Y x x  x x new service 
Disseminate 
Trial Results 
N x   x x new service 
Patient Y x x x x x  
Registration Y x x x x x  
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Based on the litmus test, the Service Model is updated, as shown in Table 15, where the 
Status column has been updated to be either “A” to indicate the associated service has 
been approved for implementation or “E” to indicate the associated service will be 
exposed.  The Services column in the Goal-Service Model is updated, as shown in Table 
16. 
   
Table 15. Service Model: Service Portfolio After Litmus Test. 
Service Description Status Associations 
Function / 
Process 
Goal Asset 
Recruit Patient 
Advocate 
Manage list of potential patient 
advocates. 
E Pre- Study 1.1.1 
2.1 
3 
 
Register Patient 
Advocate 
Register patient advocate as participant 
in clinical trial. 
E Initiate Study 1.1.1 
2.1 
3 
 
Manage Trial 
Candidate 
Manage list of potential subjects, 
including information about them. 
E Conduct Study 1.1 
3 
 
Request Subject 
Referral 
Request to register subject into a trial A Conduct Study 1.1 
3 
 
Manage Referral 
Request 
Review request to register subject into 
a trial. 
A Conduct Study 1.1 
3 
 
Monitor Subject Generate a view of trial data for a 
specified subject, submit questions, 
and review answers. 
A Conduct Study 1.2 
2.1 
3 
 
Monitor Trial 
Data 
Generate a view interim trial data. A Conduct Study 1.2 
3 
 
Obtain Trial 
Data 
Generate a report of trial data or 
outcomes. 
E Report and 
Analyze Study 
1.2.1 
2.1.1 
 
Disseminate 
Trial Results 
Send a final report in a format that can 
be viewed. 
A Post-Study 1.2.1 
2.1.1 
 
Patient Manage and query patients E Conduct Study 1.2 CTS 
Registration Manage and query registration E Conduct Study 1.1 CTS 
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Table 16. Goal-Service Model After Litmus Test (Exposed Services Only). 
Goal or Sub-Goal KPIs Metric Services 
1: Reduce clinical 
trial costs. 
Reduce clinical trial costs by 
w%. 
Record 
recruitment 
spending. 
 
1.1: Improve trial 
subject recruitment 
rates. 
 
X% increase in the number 
trials that successfully enroll 
the required number of 
eligible subjects within the 
planned recruitment period. 
Record planned 
enrollment time 
lines versus 
actual. 
 
Manage Trial 
Candidate 
1.1.1: Increase trust 
between clinical 
researchers and the 
communities where 
they operate. 
Reflected in KPI for Goal 1.1. n/a Recruit Patient 
Advocate 
Register Patient 
Advocate 
1.2: Improve trial 
subject retention 
rates. 
Reduce drop-out rate by y%. 
 
Record status of 
each subject 
enrolled in a trial. 
 
1.2.1: Increase trust 
between clinical 
researchers and the 
communities where 
they operate. 
Reflected in KPI for Goal 1.2. n/a  
2: Improve quality of 
trial data. 
Reflected in KPI for Goal 2.1. n/a  
2.1: Improve quality 
of data submitted by 
trial subjects. 
Reduce the number of trial 
data points that must be 
omitted from the study by z%. 
Record status of 
data points for a 
given trial 
subject. 
Recruit Patient 
Advocate 
Register Patient 
Advocate 
2.1.1: Increase trust 
between clinical 
researchers and the 
communities where 
they operate. 
Reflected in KPI for Goal 2.1. n/a  
3: Receive effective 
treatment for a health 
concern. 
Medical condition is cured or 
successfully managed. 
Recorded as part 
of trial execution. 
Identified during 
trial planning 
Recruit Patient 
Advocate 
Register Patient 
Advocate 
Manage Trial 
Candidate 
  
 
  b) Service specification:  The purpose of this task is to define each service in greater 
detail, including the service dependencies, composition, flows, and non-functional 
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requirements.  The output is a Service Model that is updated with this information. 
 
RUP/SOMA defines two types of dependencies, functional ones and temporal ones.  
When a service is a composition of other services, the composing service has a functional 
or Type 1 dependency on the composed services.  When services are used in the context 
of business processes, the services may have to be executed in a particular order.  These 
services have temporal or Type 2 dependencies and need to be choreographed. 
 
None of the new exposed services have Type 1 dependencies.  Manage Referral Request 
has Type 1 dependencies on Patient and Registration.  However, it is has not been 
earmarked as an exposed service.  The temporal dependencies are shown in Figure 12 
using a SOMA notational form. 
 
 
Figure 12. Service Model: temporal (Type 2) dependencies. 
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Service composition is used to group together a set of short-running non-interruptible 
processes or a set of long-running processes.  In this study, composition is not required 
since these processes are short-running and interruptible. 
 
Nonfunctional requirements, such as availability, operational window size, response time, 
and peak throughput, are considerations that should be noted.  The services in this study 
do not have nonfunctional requirements beyond typical web application response times. 
 
  c) Message design:  The purpose of this task is to develop a message design model that 
describes the message exchange patterns.  The output is an updated Service Model that 
identifies the operations for each service along with its signature. 
 
The RUP/SOMA template requires a separate table for each service.   To preserve space, 
a different format containing the same information was used.  Table 17 includes 
messages for each new exposed service. 
 
Table 17. Service Model: Service Messages. 
Service Topic Input Message Output Message 
Recruit Patient 
Advocate 
createPatientAdvocate PatientAdvocate  
updatePatientAdvocate PatientAdvocate PatientAdvocate 
deletePatientAdvocate PatientAdvocate  
findPatientAdvocate PatientAdvocate PatientAdvocate 
Register Patient 
Advocate 
createRegistration AdvocateRegistration  
updateRegistration AdvocateRegistration PatientAdvocate 
deleteRegistration AdvocateRegistration  
findRegistration AdvocateRegistration PatientAdvocate 
Manage Trial 
Candidate 
createSubject Subject  
update Subject Subject Subject 
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deleteSubject Subject  
findSubject Subject Subject 
Obtain Trial Data getSingleSubject TrialDataQuery SubjectData 
getMultipleSubjects TrialDataQuery MultiSubjectData 
 
 
  d) Identify security patterns:  The purpose of this task is to identify and select security 
patterns that will ensure security requirements will be met.  The output is an updated 
Software Architecture Document. 
 
There are three key security patterns for these services: 1) Identity and Authentication; 2) 
Authorization; and 3) Message Protection.  These patterns are required because of the 
sensitive and personal nature of the information being handled. 
 
  e) Document service state-management decisions:  This is a SOMA task that is not 
included in the RUP/SOMA process description.  The purpose of this task is to determine 
if state information must be maintained across the invocation of composed services. 
 
Subject will assigned various states (e.g., candidate or eligible) as part of executing 
business processes.  However, the state does not need to be maintained across composed 
services.  No other entities require state information.   
 
 2) Perform Subsystem Analysis:  This activity is used to understand the relevant 
subsystems within the business and map them to their IT counterparts.  Table 18 
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summarizes the tasks and their inputs and outputs. 
 
Table 18. Perform Service Specification Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Subsystem design Business Analysis Model 
Design Subsystem 
Interface 
Design Model 
 
 
  a) Subsystem design (SOA):  The purpose of this task is to link business models to their 
counterparts.  To do this, functional areas are mapped to subsystems.  Then the 
subsystem behaviors, internal structures, and dependencies are defined.  The output is a 
component-level Design Model. 
 
The first step in this task is to use output from functional area analysis to identify the 
supporting subsystems.  In Table 19, functional areas of interest in this study are mapped 
to existing subsystems.  To implement the new capabilities introduced in this study, a 
new functional area, Community, has been added.  The new subsystems are based on the 
business object being processed.  Refer to Figure 17 for depictions of each subsystem. 
 
Table 19. Design Model: Functional Area Analysis of Clinical Trials Function. 
Domain Functional Area Subsystem Description 
Clinical 
Trials 
Clinical 
Researchers 
Patient Provides patient-related functions. 
Registration Provides registration-related functions. 
Community 
 
Patient 
Advocate 
Provides functions to manage patient 
advocates. 
Subject Provides functions to manage potential 
trial subjects. 
TrialData Provides functions to provide reports 
about trial data. 
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The next step is to review the subsystems and to identify any dependencies among them.  
A detailed description of each subsystem associated with CTS and the relationships 
among them is provided in [18] and is not duplicated here.  The dependencies associated 
with the new subsystems are shown in Table 20. 
 
Table 20. Design Model: Subsystem Dependencies. 
Subsystem Depends On  Description 
Patient 
Advocate 
none n/a 
Subject Patient 
Advocate 
The Patient Advocate system is used to ensure that the user is 
authorized to access a particular candidate’s information. 
Patient The Patient subsystem is used to enter information about a 
patient into the CTMS and must be completed before a subject 
can be referred to a trial. 
Register The Register subsystem is used to register the subject. 
Trial Data Patient 
Advocate 
The Patient Advocate system is used to ensure that the user is 
authorized to access a particular candidate’s information. 
Subject The Subject system is used to ensure that the user is authorized 
to access a particular candidate’s information. 
 
 
The final step is to identify the service components, function components, and technical 
components.  A service that is assigned to a subsystem typically becomes a service 
component.  Functional components provide additional business functions to the service 
component and are often type managers.  Technical components provide functions that 
typically cross business domains.  Table 21 identifies these components.   
 
Upon analysis of subsystem interdependencies, it was determined that additional 
technical components are needed to provide function to respond to inquiries about the 
status of a patient advocate or subject.  Confirm Subject Status and Confirm Patient 
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Advocate Status have been added as technical components.   
 
Table 21. Design Model: Component Identification. 
Services Service Component Functional 
Component 
Technical Component 
Patient 
Advocate 
Subject Trial 
Data 
 Confirm 
Patient 
Advocate 
Status 
Confirm 
Subject 
Status 
Obtain 
Trial 
Data 
Recruit 
Patient 
Advocate 
   x    
Register 
Patient 
Advocate 
x    x   
Manage 
Trial 
Candidate 
   x x x  
Obtain Trial 
Data 
      x 
 
 
3) Perform Component Specification:  This activity is used to specify more details about 
the service components.  Table 22 summarizes the tasks and their inputs and outputs. 
 
Table 22. Perform Service Specification Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Component 
specification 
Design Subsystem 
Service Component (Design 
Model) 
Service Component (Design 
Model) 
 
 
  a) Component specification (SOA):  The purpose of this task is to elaborate on the 
service component design.  This elaboration includes: 
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• Modeling the component flows.  This is typically a Universal Markup Language 
(UML) sequence diagram.  However, for this study, component flows are 
represented using Petri nets.  The same Petri net can be used for Recruit Patient 
Advocate and Manage Trial Candidate since both require create, read, update, and 
delete (CRUD) processes, as shown in Figure 13.  The Petri net for Register 
Patient Advocate is shown in Figure 14.  Diagram annotations are in Table 23 and 
Table 24. 
 
These Petri nets were developed and validated using Platform Independent Petri 
net Editor 2.4 (PIPE2) [43]. 
 
 
Figure 13. Design Model: Petri net for CRUD. 
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Table 23. Annotations for Recruit Patient Advocate and Manage Trial Candidate. 
Place /  
Transition 
Interpretation Description 
P0 User Not logged in 
P1 Web Page Application logon page; web server is available 
P2 Data List of authorized users  
P3 User Logged in 
P4 Web Page Patient Advocates or Trial Candidates page (home page) 
P5 Database Connection to Advocates or Candidates database 
P6 Data Added database entry 
P7 Data Retrieved database entry 
P8 Data Updated database entry 
P9 Data Deleted database entry 
T0 Task Log in user 
T1 Task Display home page 
T2 Task Obtain database thread; add a patient advocate or trial candidate 
T3 Task Release database thread; display home page  
T4 Task Obtain database thread; retrieve database entry for patient 
advocate or trial candidate 
T5 Task Release database thread; display home page 
T6 Task Update database entry 
T7 Task Release database thread; display home page 
T8 Task Delete database entry 
T9 Task Release database thread; display home page 
T10 Task Log out user 
 
 
 
Figure 14. Design Model: Petri net for Register Patient Advocate. 
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Table 24. Annotations for Register Patient Advocate. 
Place /  
Transition 
Interpretation Description 
P0 User Not logged in 
P1 Web Page Application logon page (web server is available) 
P2 Data List of authorized users  
P3 User Logged in 
P4 Web Page Patient Advocates page 
P5 Database Connection to Advocates database 
P6 Data Retrieved database entry 
P7 Database Connection to Trials database 
P8 Data Registered patient advocate 
P9 Data Dropped patient advocate 
T0 Task Log in user 
T1 Task Display Patient Advocates page (home page) 
T2 Task Obtain Advocates database thread; retrieve database entry for 
patient advocate 
T3 Task Obtain Trials database thread; register patient advocate to trial 
T4 Task Release database threads; display home page 
T5 Task Obtain Trials database thread; drop patient advocate from trial 
T6 Task Release database threads; display home page 
T7 Task Log out user 
 
• Identifying events and messages.  A high level specification was provided in the 
Service Model.  The specification of events and messages is part of normal design 
activity for web services and is not unique to SOMA so this task is not covered in 
this study. 
• Specifying component attributes.  This includes: 1) component properties and 
attributes; 2) rules; 3) variations; 4) dependencies on other components; 5) any 
composition of functional or technical components; 6) a list of the services 
provided; and 7) a list of the services required.  The attributes that are unique to 
SOMA have been addressed in previous steps.  Refinement is not unique to 
SOMA, so this task is not covered in this study. 
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• Creating a component class diagram that shows the relationships between the 
functional and technical components of each service component.  This will be 
used to conduct variability analysis.  Component models are created to depict the 
relationships among the components.  Figure 15 shows the relationship between 
ManageTrialCandidate and ConfirmPatientAdvocateStatus.   
 
 
Figure 15. Design Model: relationship of components in Subject subsystem. 
  
• Allocating components to layers.  The service components have been allocated to 
`the Service Component layer, as illustrated in Figure 16. 
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Figure 16. Design Model: architectural layers. 
  
C. Service Realization. 
This is the third phase of RUP/SOMA.  During this phase, the Service Model is updated 
to document realization decisions; and a proof-of-concept is conducted.  Service 
Realization consists of one activity, Realization Decisions. 
 
 1) Realization Decisions:  This activity is used to evaluate various options to determine 
how a service will be built.  Table 25 summarizes the tasks and their inputs and outputs. 
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Table 25. Realization Decisions Tasks, Inputs, and Outputs. 
Task Inputs Outputs 
Document service realization 
decisions 
Reference Architecture 
Service Model 
Software Architecture 
Document 
Design Model 
Component specification Design Subsystem 
Service Component 
(Design Model) 
Service Component 
(Design Model) 
Construct architectural proof-of-
concept 
Service Model  
Assess viability of architectural 
proof-of-concept 
Architectural Proof-of-
Concept 
Business Case 
Glossary 
Risk List 
Vision 
Reference Architecture 
Review Record 
 
 
  a) Document service realization decisions:  The purpose of this task is to determine a 
sourcing approach.  The output is a Design Model. 
 
RUP/SOMA describes a number of options for how to realize a service.  They include:  
1) developing the service in-house; 2) purchasing code for the service so it can be hosted 
internally; 3) extracting and transforming functionality from an existing code source; 4) 
subscribing to an existing publish-subscribe service; 5) creating a wrapper around legacy 
code; or 6) using a web service offered by an outside business.  The decisions for the 
Community enterprise component are documented in Table 26.  In all cases, the decision 
to build in-house was due to lack of awareness of an existing service or source code.  The 
Patient and Registration services are realized through web services offered by a third 
party. 
  
84 
 
Table 26. Service Model: Service Realization Decisions. 
Enterprise 
Component 
Realized 
Service 
Functional & Technical 
Components 
Realization 
Decision 
Community Subject ManageTrialCandidate Build in-house 
ConfirmSubjectStatus Build in-house 
Patient 
Advocate 
RecruitPatientAdvocate Build in-house 
RegisterPatientAdvocate Build in-house 
ConfirmPatientAdvocateStatus Build in-house 
Trial Data ObtainTrialData Build in-house 
 
 
  b) Component specification (SOA):  The purpose of this task is to allocate components 
to layers.  This is a reiteration of the step performed during Service Specification.  No 
update is required. 
 
  c) Construct architectural proof-of-concept:  This is a reiteration of the step performed 
during Service Identification.  During this phase, additional details about the services 
may reveal additional issues to consider.   
 
The proof-of-concept is focused on the high risk areas of the architecture.  In this study, 
the proposal to use third-party services brings significant risks, such as loss of service, 
data loss, performance problems, unreliability of service, lack of interoperability, and 
format changes [44].  Because of this, the proof-of-concept will be a working prototype 
designed to demonstrate the feasibility of using caBIG Integration Hub to access the 
Patient service.  The goal of the prototype is to use the Patient service to enroll a patient 
that has been defined in a separate application [45]. 
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  d) Assess viability of architectural proof-of-concept:  The purpose of this task is to 
define how an Architectural Proof-of-Concept will be evaluated against Architectural 
Requirements and Risks.  Evaluation criteria are determined based on requirements that 
are significant from an architectural perspective.  The evaluation results are reviewed to 
determine if these requirements can be met.  If not, the project team may want to re-
evaluate the requirement priorities.   
 
As indicated earlier, the highest risk aspects of the architecture are associated with use of 
third-party services.  Evaluation criteria involve the answers to these questions: 
• Can authentication and authorization be implemented to ensure secure access to 
information? 
• Do the services provide the capability necessary to implement the complete 
solution? 
• Will the performance characteristics allow the solution to scale? 
• Are the called services sufficiently stable from a capability, interface, and quality 
perspective? 
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VIII  Evaluation of Proposed Solution 
 
After the Service Model and Design Model are created and technically validated via an 
architectural proof-of-concept, it is appropriate to evaluate the proposed solution against 
the original project goals, requirements, and expected benefits. 
 
Figure 17 shows the overall architecture of the proposed solution.  It includes service 
components, web application components, and the relationships among the components.  
Refer to Appendix I for a model of the Monitor Subject application using a Petri net. 
 
 
Figure 17. Solution architecture. 
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A. Evaluation Against Goals. 
Because SOMA includes the Goal-Service Modeling step, there is a clear relationship 
between business goals and the services being proposed, as shown in Table 27.  As the 
metrics identified in Table 16 are collected and analyzed, there will be objective evidence 
to show that these services are effective in meeting business goals. 
 
Table 27. Goal-Service Summary. 
Goal or Sub-Goal Services 
1: Reduce clinical trial costs.  
1.1: Improve trial subject recruitment rates. Manage Trial Candidate 
Confirm Subject Status 
1.1.1: Increase trust between clinical researchers and the 
communities where they operate. 
Recruit Patient Advocate 
Register Patient Advocate 
Confirm Patient Advocate Status 
1.2: Improve trial subject retention rates. Obtain Trial Data 
1.2.1: Increase trust between clinical researchers and the 
communities where they operate. 
Obtain Trial Data 
2: Improve quality of trial data.  
2.1: Improve quality of data submitted by trial subjects. Recruit Patient Advocate 
Register Patient Advocate 
2.1.1: Increase trust between clinical researchers and the 
communities where they operate. 
Obtain Trial Data 
3: Receive effective treatment for a health concern. Recruit Patient Advocate 
Register Patient Advocate 
Manage Trial Candidate 
Obtain Trial Data 
 
 
B. Evaluation Against Requirements. 
Some of the business requirements identified in Section VI will be addressed through 
implementation of business processes that do not require an IT solution.  Table 28 shows 
the mapping between the business requirements and the new services that are part of the 
solution.  Note that the design and architecture meet requirement A-13, even though there 
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is no specific service associated with it. 
 
Table 28. Business Requirements Mapped to Services. 
Business Requirement Business 
Process 
New Business 
Use Case 
Service 
A-1. Increase 
awareness 
Perform 
Outreach 
none n/a 
A-2. Educate 
physicians  
Perform 
Outreach 
none n/a 
A-3. Incorporate 
community perspective 
All existing 
business 
processes, 
where 
appropriate 
none n/a 
A-4. Provide culturally 
appropriate education  
Perform 
Outreach 
none n/a 
A-5. Provide culturally 
appropriate informed 
consent 
All informed 
consent 
processes 
none n/a 
A-6. Incorporate 
community needs and 
priorities 
All existing 
business 
processes, 
where 
appropriate 
none n/a 
A-7. Include members 
of the community in 
all stages of the 
clinical trials process 
All existing 
business 
processes, 
where 
appropriate 
none n/a 
A-8. Engage and train 
research advocates 
Manage Patient 
Advocates 
Refer Patient 
Advocate 
Refer Subject 
Recruit Patient 
Advocate 
Train Patient 
Advocate 
Manage Trial 
Candidate 
Request Subject 
Referral 
Manage Referral 
Request 
RecruitPatientAdvocate 
RegisterPatientAdvocate 
ManageTrialCandidate 
ConfirmPatientAdvocateStatus 
ConfirmSubjectStatus 
A-9. Engage 
community physicians 
and healthcare 
providers 
All existing 
business 
processes, 
where 
appropriate 
none n/a 
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A-10. Ensure follow-
through on 
commitments to trial 
subjects 
not applicable none n/a 
A-11. Ensure ongoing 
one-on-one 
communication 
Monitor Study Monitor 
  Subject 
Monitor Trial 
  Data 
Obtain Trial 
  Data 
ObtainTrialData 
A-12. Provide health 
education to trial 
subjects 
Provide Health 
Education 
none n/a 
A-13. Provide a single, 
consistent interface 
not applicable none n/a 
A-14. Disseminate 
project outcomes 
Disseminate 
Trial Results 
Disseminate 
  Trial 
  Results 
Obtain Trial Data 
ObtainTrialData 
 
 
In addition to business requirements, some architectural requirements were identified in 
Section V.C:  
• Requirement:  The solution must be integrated with existing systems. 
Assessment:  This is largely possible because CTS is services-based.  If different 
systems had been chosen as the basis for this study, it might have been more 
difficult to achieve integration. 
• Requirement:  The system must accommodate multiple CTMS and CDMS back-
ends. 
Assessment:  Because CTMSs and CDMSs are accessed via services, the 
architecture is not limited to specific back-end systems.  However, there may be 
limitations based on the ability to create a service wrapper around a system. 
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• Requirement:  The solution must be sufficiently flexible to accommodate the 
specific requirements of each supported clinical trial. 
Assessment:  Because reusable services will be created and made public, solution 
developers can mix and match them to accommodate their specific needs.  It is 
easier for them to fill in the missing functionality because the services have well-
defined interfaces. 
• Requirement:  The solution must support rapid deployment and be cost-effective. 
Assessment:  The expectation is that there will be less need to build functionality 
from scratch.  Solution developers should be able to spend less time implementing 
core capabilities to support their trust-building activities so they can focus on 
issues that are unique to a particular trial, such as translation of user interfaces. 
 
C. Evaluation Against the Case Study. 
As stated in Section III, trust in the Hispanic community is influenced by common 
cultural characteristics.  Table 29 shows the linkage between these cultural characteristics 
and business processes or services. 
 
In support of the case study, patient advocates recruited from the San Jose Hispanic 
community would be managed using Recruit Patient Advocate and Register Patient 
Advocate.  This would include family members, community-based healthcare providers, 
or primary care physicians.   
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Table 29. Linkage between Trust Issues and Services. 
Characteristic Business Process Support Supporting Service Support 
Language Develop Informed Consent Form 
Obtain Informed Consent 
none 
Family Perform Outreach 
Manage Patient Advocates 
Disseminate Trial Results 
Recruit Patient Advocate 
Register Patient Advocate 
Obtain Trial Data 
Respect Monitor Study 
Disseminate Trial Results 
Obtain Trial Data 
Personal Relationships Refer Subject 
Monitor Study 
Manage Trial Candidate 
Obtain Trial Data 
 
 
Healthcare providers would be trained about the benefits of participating in clinical trials 
and encouraged to refer patients using Manage Trial Candidate.  Because the eligibility 
requirements of the case study can be stated as rules that can be verified electronically, a 
custom-built service to automatically verify eligibility could be developed and 
incorporated into the solution.  Because the solution is an SOA, incorporating this change 
should be straight-forward. 
 
Once the trial started, the trial subject would be able to view all trial data collected to date 
and perhaps view trend data, such as changes in BMI over time, using Obtain Trial Data.  
The subject’s healthcare provider would also be able to use the service to view the 
patient’s progress and, perhaps, to order lab tests to monitor the effects of better diet and 
improved BMI on other health indicators, such as blood sugar, cholesterol levels, and 
blood pressure.  
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D. Summary. 
Table 30 contains a summary of the evaluation.  The primary business goals can be met if 
trust is improved through use of the proposed solution.  Most of the architectural 
requirements have been realized.  Linkages between these services and increased trust in 
the San Jose Hispanic community were demonstrated. 
 
Table 30. Summary of Solution Evaluation. 
Project Goal Requirement  Goal Met or Requirement Met  
Goal 
1. Reduce clinical trial costs. Yes, due to improved trust 
2. Improve quality of trial data. Yes, due to improved trust 
3. Receive effective treatment for a health concern. Will depend on effectiveness of 
treatments under study 
Requirement 
The solution must be integrated with existing systems. Yes 
The solution must be sufficiently flexible to accommodate 
the specific requirements of each supported clinical trial. 
Yes 
The solution must support rapid deployment and be cost-
effective. 
Too early to determine 
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IX  Summary and Conclusions 
 
The technical solution conceived at the beginning of this study to address trust-building 
between clinical researchers and the San Jose Hispanic community was fairly 
straightforward.  The intent was to design a services-based application that would:  1) 
manage a database of potential trial subjects, healthcare providers, and patient advocates; 
2) give trial subjects and their primary healthcare providers access to trial data; and 3) 
provide a means for community members and clinical researchers to interact with each 
other.  
 
As a stand-alone application for a single trial, this would have been simple and quick to 
implement.  However, that would have been a short-sighted solution.  There might be 
duplicate or overlapping efforts by different IT staff; the community might experience a 
lack of continuity from trial to trial due to lack of data sharing; or relationships 
established during one trial might have to be rebuilt in the next.  Managing each clinical 
trial in the community differently would not encourage trust.  
 
A better approach was to find a way to implement a solution that could provide a 
consistent interface to the community while accommodating the various CTMSs used by 
different researchers.  An SOA approach was explored using the RUP/SOMA 
methodology. 
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Because RUP/SOMA assumes that requirements analysis has been completed, a 
methodology was developed to translate non-functional wants and needs to technical 
requirements.  The resulting requirements specification became input to the RUP/SOMA 
methodology. 
 
RUP/SOMA focuses on the architecture and design of external web services, using 
SOMA notations and Unified Modeling Language (UML) to model them.   
Petri nets were used to simulate flows among web services and validate the architecture. 
 
The solution was evaluated against the original business goals and requirements.  The 
methodology for deriving the requirements provided linkage from the non-functional 
wants and needs to business processes to technical requirements.  RUP/SOMA provided 
linkage from the business goals to service components.  Because these two 
methodologies maintained traceability throughout the definition of the architecture, the 
result addressed all goals and requirements. 
 
A. Next Steps. 
The next steps for this study are to plan and execute the architectural proof-of-concept.  
The functional requirements and use case for the proof-of-concept have been defined 
[45].  Initial investigation of the service messages associated with Patient and the 
protocols for using Integration Hub has been completed.  Additional details must be 
added to the component specification, to provide greater details about how to invoke the 
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Patient service and deal with any errors from the service. 
 
A number of issues arose that require consideration:  First, the services being provided by 
caBIG are being defined and prototyped concurrently with this study.  Because of this, 
service capabilities, interfaces, and protocols have been subject to change.  Second, to 
test this system, the entire caBIG infrastructure, including caGRID, must be installed.  
Further work on the proof-of-concept should be delayed until the required third-party 
services are implemented and stable and a test harness is in place. 
 
After completion of the proof-of-concept, implementation, deployment, and management 
should follow.  The solution should be re-evaluated at key checkpoints during the service 
life cycle to ensure it continues to meet original intents. 
 
It should be noted that the methodology defined in Section VI is not domain-specific so it 
may be sufficiently general and complete to be used for transforming any non-functional 
requirements into implementable technical requirements.  Further work is needed to 
confirm this. 
 
B. Recommendations. 
This paper concludes with some observations about the RUP/SOMA methodology, along 
with recommendations for projects contemplating its use. 
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 1) Project Selection:  If a project is small and limited in scope, the additional effort 
expended to follow the RUP/SOMA methodology may not yield any measurable benefit.  
The SOA governance process should have criteria for determining which projects are in 
the scope of the SOA and which are not.  This lets the enterprise focus resources and 
efforts on the solutions most likely to yield high-value services. 
 
This study also demonstrated that use of the RUP/SOMA methodology does not have to 
be restricted to an individual business.  It can also be used to architect a solution for a 
well-defined business process that is shared by an industry. 
  
 2) Consideration for the Existing IT Environment:  RUP/SOMA can be used to architect 
services in both SOA and non-SOA environments.  However, it is a much more difficult 
task to use the methodology if the enterprise has not already adopted some kind of formal 
IT architecture or if it has not documented an inventory of its software. 
 
The operation-first approach suggests a comprehensive search for reuse opportunities 
throughout the entire enterprise.  This can be very time-consuming in an environment 
where needed information is not available.  When architecting a relatively small solution 
of limited scope such as the trust-building application, starting the service identification 
at the sub-function level may be more cost-effective, as the opportunities for reuse are 
more likely within that sub-function or the immediate function enclosing it. 
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 3) Business Goals:  RUP/SOMA focuses on business goals; but many times the effect a 
small project has on the top business goals can be minimal.  When performing goal-
service modeling, it is important to start with goals at an appropriate level within the 
business where the positive impacts of the services can actually be discerned. 
 
 4) RUP/SOMA and the Software Development Life Cycle:  To perform service 
identification adequately, the software architect must have a clear understanding of the 
requirements and some idea of how those requirements will be met from a functional 
perspective.  Also, during the services realization phase, the decisions there can 
significantly impact the software development schedules, test plans, and resource 
allocations.   
 
To be effective, the RUP/SOMA methodology must be tightly integrated with the normal 
software development life cycle (SDLC) so external services design and architecture are 
performed in parallel with activities for the other components of the project.  Buy-versus-
make decisions should be made as early as possible to enable better project planning. 
 
 5) SOA Metrics:  Even though a service is perfectly aligned with business goals, its 
maintenance and upkeep as a service may not be cost-effective if that service has only a 
few internal consumers.  Metrics should be identified to measure the effectiveness of 
service selection as part of SOA governance.   
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 6) SOA Governance:  During the service identification phase of RUP/SOMA, the 
mapping from business processes, as understood by the business process analyst, to 
services, as understood by the software architect, is performed.  To ensure the mapping 
across these two disciplines is correct, it is highly recommended that SOA governance 
include policies regarding model reviews and approvals.  Similarly, goal-service models 
should be reviewed by a cross-functional team. 
 
All models should be retained and be accessible for use by other projects in the enterprise 
to minimize duplicate efforts.  These models should be reviewed periodically to ensure 
they still reflect current business goals and practices. 
 
In conclusion, even though the RUP/SOMA methodology focuses on an enterprise-wide 
SOA, it is possible to use the methodology within a single business function or sub-
function as the starting point for an SOA.  By narrowing the scope, the architect can 
identify reusable components in a more cost-effective way.  Other strategies for success 
are tighter integration with the SDLC, identification of metrics to measure the 
effectiveness of service selection, and model review.
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Appendix A  Sample Questions to Elicit Domain Solutions 
 
Prior to architecting a solution, it is important to understand what the solution 
requirements are.  One way to determine solution requirements is by interviewing clinical 
trial participants to understand the underlying causes for lack of trust.  Figure 18, Figure 
19, Figure 20, and Figure 21 are samples of questions an architect can ask to get a better 
understanding of the requirements.  For this study, solution requirements were 
determined by [4]-[9], [11], [12]. 
 
Questions for Clinical Researchers 
 
1. Research history 
a. Have you conducted any clinical research targeted at the Hispanic community within 
the last 5 years? If no, skip to 1c. 
b. What was the purpose of the most recent one? Skip to 2. 
c. Have you conducted any clinical research within the last 5 years that may have 
included members of the Hispanic community? If no, skip to 8. 
d. What was the purpose of the most recent one?  
These questions are for the most recent study. 
2. Participants - data 
a. How many participants did you plan to include in the study? 
b. How did you go about finding participants? (Examples:  advertising in papers, direct 
mail, through community clinics) 
c. Was any study information translated in Spanish? If so, what? 
d. What was the actual number of participants? 
e. What tools did you use to manage recruitment? Patient data? Were you satisfied with 
them? Why/why not? 
3. Participants - observations 
a. What techniques were most successful in recruiting participants? 
b. Were there any issues associated with informed consent? 
c. Are there any things you would do differently in the recruitment process? 
d. What techniques or tools, if any, would improve your recruiting process? 
4. Managing participation - data  
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a. How long was each participant expected to participate? 
b. What were participants required to do? 
c. How were study requirements communicated to each participant? Were they in 
Spanish? 
d. How did you monitor patient participation? 
e. How often did you contact them directly? 
f. If a participant had questions or concerns, how did they contact you? 
g. What tools did you use to manage participation? Patient data? Were you satisfied with 
them? Why/why not? 
5. Managing participation – observations 
a. Were you satisfied with the quality of input from participants? Why/why not? 
b. Are there any actions you would recommend for improving the quality of input in 
future studies? 
c. What techniques or tools, if any, would help you manage participation better? 
d. What would help you manage patient data better? 
6. Interaction with primary care physicians 
a. Were participants’ primary care physicians informed of their participation in the study? 
If so, how? 
b. Was there a way for physician to communicate directly with the researchers during the 
study? If so, how? 
c. Was participant data made available to physicians during the study? If so, how? 
d. Do you think greater involvement by patient primary care physicians would have 
resulted in better participation or higher quality results? 
e. If primary care physicians involved:  What tools did you use to communicate with 
physicians? Were you satisfied with them? Why/why not? 
7. Interaction with community leaders 
a. Were any community leaders involved in your study? If yes, what was their role? 
b. How did you communicate with them? 
c. What tools did you use? Were you satisfied with them? Why/why not? 
8. Thank researcher for his/her time. 
Figure 18. Sample questions for clinical researchers. 
 
Questions for Community Leaders  
 
1. Local issues and concerns 
a. What are the most important health issues in the Hispanic community? 
2. Encouraging participation in clinical research 
a. Do you think it’s important for the local Hispanic community to participate in clinical 
research focused on these issues? Why or why not? 
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b. Are you aware of any clinical research in the last 5 years that has been focused on 
these issues? 
c. If yes, how did you hear about it? 
d. If yes, did you actively promote participation in that research? Why or why not? If yes, 
how? 
3. Engaging leaders 
a. Were you included in the planning of the study? If so, how? 
b. Were you kept informed of progress? If so, how? 
c. How important was it to you to be included in study planning and execution? 
d. What information would be most useful to you? 
Figure 19. Sample questions for community leaders. 
 
Questions for Healthcare Professionals 
 
1. Encouraging participation in clinical research 
a. Are you aware of any clinical research in the last 5 years that would be beneficial to 
your Hispanic patients? 
b. If yes, how did you hear about it? 
c. If yes, did you actively promote participation in that research? Why or why not? If yes, 
how? 
2. Engaging healthcare professionals 
a. Were you included in the planning of the study? If so, how? 
b. Were you kept informed of progress? If so, how? 
c. How important was it to you to be included in study planning and execution? 
d. What information would be most useful to you? 
Figure 20. Sample questions for healthcare professionals. 
 
Questions for Participants 
(To ensure privacy, will not ask about the specifics of the study; focus on the process.) 
 
1. Informed consent 
a. How was the purpose of the study and the risks explained to you? 
b. Did you feel the researchers communicated this clearly to you? 
2. Study process 
a. How did researchers explain what was required from you? 
b. How did you communicate with researchers during the study? How often? 
c. If you had questions or concerns during the study, how could you contact a researcher? 
Did you have to do that during the study? If so, were you happy with the 
answer/resolution? 
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d. Did you participate for the full planned period? If not, why not? 
3. Follow-up 
a. When did your participation in the study end? 
b. Did researchers contact you any time after the end of your participation? If so, why? If 
not, would you want them do? 
c. Were you informed of the overall results of the study? If so, how? 
4. Satisfaction 
a. Were you satisfied with your communications with researchers? 
b. If you had the opportunity to participate in another study, would you? Why/why not? 
c. Would you personally recommend participation to others? If not, why not? 
Figure 21. Sample questions for participants. 
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Appendix B  General Trust-Building Model 
 
Merriam-Webster Online Dictionary defines trustworthiness as “worthy of confidence” 
[46].   Lewicki and Tomlinson [47] further assert that assessment of an individual’s 
trustworthiness is based on three dimensions of trustworthy behavior.  These dimensions 
are ability, integrity, and benevolence.  The more an individual exhibits these behaviors, 
the more that person is deemed trustworthy.  Evaluation is based on questions such as:  Is 
this individual competent?  Based on past actions, is this individual truthful, does the 
individual follow through on commitments, and has the individual acted fairly? Is this 
individual concerned about my welfare? 
 
Although these dimensions were defined for individual trustworthiness, they were used as 
part of this study to evaluate whether or not the solutions proposed in Section II could 
improve trustworthiness of researchers from the perspective of members of the San Jose 
Hispanic community.  Figure 22 maps the problem themes identified in Section II to the 
trust dimensions defined by Lewicki and Tomlinson [47].  The problem themes that 
cannot be mapped directly to one of the trust dimensions are aspects that influence an 
individual’s assessment of trustworthiness.  This is illustrated in the upper left corner of 
Figure 22. 
 
Based on this mapping, this study concludes that a solution addressing these problem 
themes will increase community trust in clinical research and will positively impact a 
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community’s assessment of clinical research trustworthiness. 
 
 
Figure 22. Mapping problem themes to dimensions of trust. 
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Appendix C  Final Report Summary from NIH Roadmap Projects 
 
Table 31 summarizes the information technology aspects of the NIH projects and impacts, if any, on underserved communities. 
 
Table 31. Summary of Broad Agency Announcement (BAA) Report. 
Researcher Information Technology Features Technologies Used Impacts of research on 
community interactions and 
reaching underserved populations 
MCRC  
Univ of 
Michigan 
Honest Broker 
 
Registry 
Messaging 
Data transformation and 
filtering 
Security and privacy 
Administrative control 
International standards-
based protocol stack for 
biomedical data 
encoding 
3-tier 
Java 
P2P with authorized 
external applications 
Delivery of enriched clinical data 
to the PCP; extensions to the 
prompt and reminder system 
ClinfoTracker 
 
Networking capability for 
data exchange 
AGNIS  
National 
Marrow Donor 
Program 
AGNIS Platform-independent 
messaging system 
Data dictionary 
containing Common 
Data Elements (CDEs) 
Java 
Globus security model 
Grouper group 
management 
Open source 
applications 
No direct interaction with patients 
or underserved populations 
TB Trials 
Network 
Duke Univ Med 
Center 
Query Tracking System 
 
Query identification and 
tracking 
 
TB data standards 
Web service evaluated 
but not used due to cost 
Not available 
AE/SAE Tracking Reporting 
Trial management 
Web portal Forum for team member 
collaboration 
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ALCHEMIST Decision analysis model 
(economic) 
CTN Best 
Practices 
Med Center 
CTN Best Practices web site 
www.ctnbestpractices.org 
Resources related to 
institutional review boards, 
clinical sites new to research, 
regulatory requirements, etc. 
Acute Coronary 
Syndrome (ACS) data 
standards 
Open source 
Not available 
Clinical Trial Management 
System (CTMS) 
Manage information about a 
clinical research study, 
including individuals and 
organizations 
Investigator Profile Library Repository of information on 
clinical site investigators and 
staff 
Data Standards Inventory Identifies organizations 
creating or promoting 
standards 
InterTrial 
Columbia Univ 
WorkWeb Project management 
Individuals connected 
through various relationships 
to other entities 
Wiki and other social 
software 
Sites for this study were chosen 
due to existing good relationships 
with local communities 
CNICS 
UCSF 
FASTA Data transfer system de-
identifies, reformats, and 
aggregates 
 Not applicable 
HL7-HLC  Translates HL7 data to 
format required by CNICS 
sites 
MIRTH Translates HL7 to XML 
Website tools For importing, validating, 
and posting data on public 
website 
Data Entry tool for non-
electronic phenotypic data 
Consistent and reliable 
structure for manual entry 
Data analysis tools Interpret HIV treatment 
choices and medication 
categories 
CRN Harmony Clinical Research Supports clinical and Oracle Clinical Re-use of common data elements 
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Univ of 
Pennsylvania 
Informatics Platform translational research 
products 
Pharmaceutical 
Application (OPA) 
in collecting study elements 
enables researchers to consider 
characteristics of the underserved 
HMORN CCSN 
Group Health 
Cooperative 
Virtual Data Warehouse Stores laboratory data  Greater interest and willingness to 
participate in clinical research by 
selected cardiologists with access 
to program 
PRISM readability toolkit makes 
content more accessible 
Critical Care 
Decisions 
LDS Hospital 
eProtocol-insulin Protocol to calculate changes 
in IV insulin drip rate 
 Not available 
ePCRN 
Univ of 
Minnesota 
ePCRN Gateway Registration of clinical 
practices 
Security 
Locally controlled filters 
Imports Continuity of Care 
Record XML strings (CCR) 
Local identification of 
patients matching eligibility 
criteria 
Print, email, text messaging 
Specific disease management 
software 
Standardized multiple-
disease registry 
Globus Server 
ePCRN is suited for involvement 
of practices located in 
underserved areas 
Promotes better communication 
and collaboration at remote sites 
Being considered at Hispanic 
clinics in Los Angeles. 
ePCRN Research Portals Single access site for queries 
COG 
Children’s 
Oncology 
Group 
None specified  CDEs for pediatric 
blood and marrow 
transplantation 
Enhanced ability to perform pilots 
RIOS Net 
University of 
New Mexico 
RIOS Net IT infrastructure Centralized data and 
processes 
Data collection: web, 
commercial software, 
scanned, PDAs 
SQL Server All research is centered on 
underserved populations.  
Community outreach staff 
expanded communications into 
these communities.   
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Appendix D  Mapping between SOMA and RUP/SOMA 
 
Table 32 identifies the differences between SOMA and RUP/SOMA [36], [48].  Both 
methodologies consist of three major steps: 1) identification; 2) specification; and 3) 
realization.  Each step is further decomposed into activities, shown in the SOMA Activity 
column.  In the SOMA Task column, the specific tasks to be completed for an activity as 
defined by SOMA are listed.  In the RUP/SOMA Content column, the equivalent task or 
guideline is identified. 
   
Table 32. Mapping between SOMA and RUP/SOMA. 
SOMA Activity SOMA Task RUP/SOMA Content 
Service Identification 
Domain 
Decomposition 
Functional Area Analysis Functional Area Analysis 
Process Decomposition Refine a Business Use-Case 
Variation-Oriented Analysis Variability Analysis 
Goal-Service 
Modeling 
Identify Goals and Sub-goals Identify Business Goals and 
KPIs 
Identify Services for Sub-goals Identify and Associate Services 
to Goals 
Identify KPIs and Metrics for Sub-
goals and Services 
Identify Business Goals and 
KPIs  
Existing Asset 
Analysis 
Existing Asset Analysis Existing Asset Analysis 
 Data Model Analysis 
 Business Rule Analysis 
Service Specification 
Service 
Specification 
Apply Service Litmus Tests Apply Services Litmus Tests 
Model Service Dependencies Service Specification 
Model Service Composition and 
Flow 
Document Service Non-Functional 
Requirements 
Specify Service Messages Service Specification 
Message Design 
Document State Management 
Decisions 
Service Specification 
Subsystem Analysis Identify Subsystem Dependencies Subsystem Design (SOA) 
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Identify Service Component 
Identify Functional Components Component Specification (SOA) 
 Identify Technical Components 
Component 
Specification 
Specify Component Attributes 
Identify Events and Messages 
Model Component Internal Flow 
Create Component Class Diagram 
Variation-Oriented Design Variability Analysis 
Service Realization 
Realization 
Decisions 
 Document Service Realization 
Decisions 
Service Allocation Component Specification (SOA) 
Component Allocation to Layers 
Technical Feasibility Exploration Construct Architectural Proof-
of-Concept (SOA) 
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Appendix E  Service Model and Design Model 
 
The Service Model is updated throughout all phases of the RUP/SOMA methodology, 
and the Design Model is updated during the Specification phase.  Table 33 and Table 34 
contain outlines of the two models and provide indexes to sections in the main document 
where content has been defined.  
 
Table 33. Index to Service Model Content. 
RUP/SOMA Step Where 
Created 
Service Model Section Table or Figure 
Identification Service Portfolio Table 15 
Service Hierarchy Figure 8 
Specification Service Exposure Table 14 
Service Dependencies Figure 12 
Service Composition & Flow n/a 
Service Messages Table 17 
Service Non-Functional 
Requirements 
State Management Decisions 
n/a 
Realization Realization Decisions Table 26 
 
 
Table 34. Index to Design Model Content. 
RUP/SOMA Step Where Created Service Model Section Table or Figure 
Specification Functional Area Analysis Table 19 
Subsystem Dependencies Table 20 
Component Identification Table 21 
Component Internal Flow Figure 13, Figure 14 
Component Class Diagrams Figure 15 
Allocation to Architecture Layers Figure 16 
Events and Messages 
Component Attributes 
n/a 
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Appendix F  Business Process Flows 
 
Implementing RUP/SOMA requires understanding of the business process flows.  Figure 
23 shows the as-is business process flow for the clinical trials process, and Figure 24 
shows the to-be business process flow.  Manage Community is a new process that 
includes sub-processes to manage activities associated with members of the community.  
A decomposition of Manage Community business process flows is shown in Figure 25. 
 
 
Figure 23. As-is clinical trials business process. 
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Figure 24. To-be clinical trials process. 
 
 
Figure 25. Decomposition of Manage Community. 
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Appendix G  Business Actors and Business Use Case Model 
 
To identify an appropriate set of use Business Actors and Business Use Cases to review 
for refinement, an earlier version of the SOMA methodology was used [34].  In that 
version of SOMA, two business process models are developed.  The as-is model 
describes the current business; and to-be model describes the desired future business.  A 
comparison of the two models yields the business use cases that will require review. 
 
A. As-Is Business Use Case Model. 
caBIG created a business architecture model for clinical trials [37] that was used to 
represent the as-is business use case model in this study.  The business use case model is 
represented using Unified Modeling Language (UML).  Only that subset of use cases that 
are relevant to trust-building activities will be shown. 
 
caBIG identifies four categories of business use cases for Manage Clinical Research, 
shown in Figure 26.  These categories are a way of partitioning the use cases and are not 
intended to represent the business processes. 
 
 
Figure 26. Business use case categories for as-is Manage Clinical Research. 
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The use cases for Plan Study, shown in Figure 27, represent preparatory activities 
covering scientific aspects, logistics, regulatory and legal issues, and finance.  This 
includes activities such as identification of the study team, trial design, recruitment plans, 
and trial monitoring. 
 
 
Figure 27. Business use cases for as-is Plan Study. 
 
The use cases for Initiate Study, shown in Figure 28, cover study activation activities.  
This includes recording and maintaining participant information and training for trial 
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personnel. 
 
 
Figure 28. Business use cases for as-is Initiate Study. 
 
Conduct Study contains a number of relevant use cases, including one to grant access to 
data, several to manage trial subject registration, and others to manage trial subject 
schedules.  These are shown in Figure 29. 
 
The Report and Analyze Study use cases focus on regulatory and scientific reports and 
data.  Sharing Data for Collaborative purposes focuses on ad hoc reporting, as shown in 
Figure 30. 
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Figure 29. Business use cases for as-is Conduct Study. 
 
 
Figure 30. Business use cases for as-is Report and Analyze Study. 
 
B. To-Be Business Use Case Model. 
To determine which business uses cases require update and what new business use cases 
may be required, the as-is use cases are mapped against business requirements.  Table 35 
shows the business requirements derived in Section VI mapped to appropriate as-is 
business use cases. 
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Table 35. Mapping Business Requirements to As-Is Business Use Cases. 
Business Requirement As-Is Business Use 
Case 
Use Case 
Category 
To-Be Updates 
A-1. Increase awareness about 
clinical research and the clinical 
trials process through education, 
outreach, and advocacy. 
none none Add category: 
Manage Pre-Study 
Add use case: 
Perform Outreach 
A-2. Educate physicians on the 
benefits to their patients and to 
themselves of participating in 
clinical trials. 
none none See A-1. 
A-3. Incorporate a community 
perspective in the clinical trials 
process. 
none none Incorporated in 
other business use 
cases 
A-4. Build community awareness 
of researcher presence; provide 
clinical trials education that is 
culturally appropriate. 
none none See A-1. 
A-5. Use culturally appropriate 
questions and translations to 
ensure comprehension and 
accessibility of informed consent. 
Develop Informed 
Consent Form 
Plan 
Study 
none 
Conduct Study-
Specific Personnel 
Training 
Initiate 
Study 
Add actor:  Patient 
Advocate to provide 
input to training and 
optionally to provide 
training 
A-6. Incorporate community 
needs, patient perspectives, 
priorities, issues, and concerns in 
trial design. 
Determine Logistical 
Feasibility of 
Study/Trial 
Completion 
Plan 
Study 
Add actor:  Patient 
Advocate to provide 
input 
Determine Patient 
Care Funding 
Plan 
Study 
Add actor:  Patient 
Advocate to provide 
input 
A-7. Include members of the 
community in all stages of the 
clinical trials process for input, 
monitoring, and decision-making.  
This includes participation on 
review boards and on data safety 
monitoring boards. 
Define Objectives 
 
Plan 
Study 
none  
Develop Eligibility 
Criteria 
Plan 
Study 
none 
Define Ancillary 
Studies 
Plan 
Study 
none 
Describe Study 
Design and Schema 
Plan 
Study 
none 
Develop Accrual 
Plan 
Plan 
Study 
none 
Describe Patient 
Recruitment Plan 
Plan 
Study 
none 
A-8. Engage and train research 
advocates to participate in all 
stages of the clinical trials process, 
none none Add use case:  
Manage Patient 
Advocates to 
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including subject recruitment. Manage Pre-Study 
none Initiate 
Study 
Add use case: 
Register Patient 
Advocate 
none Conduct 
Study 
Add use case: 
Refer Subject 
A-9. Engage community 
physicians and healthcare 
providers as study investigators or 
by utilizing their facilities. 
Define Professional 
Qualifications of an 
Investigator Needed 
for Study Trial 
Plan 
Study 
none 
Identify and Contact 
Study/Trial Team 
Plan 
Study 
Add step:  Primary 
Investigator includes 
community 
members on the 
team as patient 
advocates  
Identify Participating 
Sites (Site 
Identification) 
Plan 
Study 
Add step:  Contact 
physicians in the 
community to elicit 
input 
A-10. Ensure follow-through on 
commitments to trial subjects. 
none none not applicable 
A-11. Ensure ongoing one-on-one 
communication with trial 
participants throughout the trial 
and be responsive to concerns. 
Develop Study 
Specific Data and 
Safety Monitoring 
Plan 
Plan 
Study 
none 
Develop Study 
Specific Plan for the 
Safety, Monitoring, 
and Evaluation of 
Participants 
Plan 
Study 
none 
none Conduct 
Study 
Add use cases: 
Monitor  Subject, 
Monitor Trial Data 
Report and Analyze 
Study 
Report 
and 
Analyze 
Study 
Add use case: 
Obtain Trial Data 
A-12. Provide health education to 
trial subjects that is sensitive to 
cultural values and beliefs. 
 
none Conduct 
Study 
Add use case: 
Provide Health 
Education 
A-13. Provide a single, consistent 
interface between the community 
and different researchers. 
none none n/a 
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A-14. Disseminate project 
outcomes. 
none none Add category:  
Manage Post-Study 
Add use case: 
Disseminate Trial 
Results 
 
The Business Requirement column contains the suggested actions identified previously; 
the As-Is Use Case column identifies an existing use case that is relevant to the business 
requirement; the Use Case Category column identifies the applicable category; and the 
To-Be Updates column identifies the changes or additions to be made to use cases or to 
use case categories.   
 
Candidates for implementation via software systems are highlighted in bold.   They are 
Manage Patient Advocates, Refer Subject, Monitor Subject, Monitor Trial Data, Obtain 
Trial Data, and Disseminate Trial Results.  Perform Outreach is focused on general 
awareness and is most likely the responsibility of functions such as marketing 
communications, so it is outside the scope of the clinical trials process.  Business use 
cases associated with training, such as Provide Health Education, may be supported via 
software systems, but will most likely be conducted in a face-to-face manner. 
 
If the to-be update is specified as “none,” the as-is use case already addresses the 
business requirement, usually through incorporation of a patient advocate in the process.  
If the to-be update is specified as “not applicable,” the business requirement describes an 
action that must be implemented through some means other than by a business process. 
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In the following figures, new or modified business use cases are highlighted with bold 
outline based on the mapping shown in Table 35.  Figure 31 shows two new categories of 
business use cases, Manage Pre-Study and Manage Post-Study.  These business use cases 
will describe activities to be conducted before or after a clinical trial.  Preliminary 
activities would include awareness activities and patient advocate and healthcare provider 
recruitment and training.  Follow-on activities would include disseminating trial results. 
 
 
Figure 31. Business use cases for to-be Manage Clinical Research. 
 
The Manage Pre-Study is a new classification of business use cases that will address 
activities that are performed to establish trust prior to a study.  Perform Outreach targets 
media, policy makers, communities, and healthcare providers.  Manage Patient 
Advocates includes activities for maintaining relationships with patient advocates, such 
as recruitment and training.  These are shown in Figure 32. 
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Figure 32. Business use cases for Manage Pre-Study. 
 
No new use cases need to be created for Plan Study.  In many cases, the as-is business 
use case already included a patient advocate as one of the actors.  Because the patient 
advocates are there to represent the patient view, many of these business use cases may 
already be capable of improving trust. 
 
Some business use cases require some modification to include participation by patient 
advocates or by physicians in the community.  These are Determine Logistical Feasibility 
of Study/Trial Completion, Determine Patient Care Funding, Identify and Contact 
Study/Trial Team, and Identify Participating Sites (Site Identification).  These business 
use cases are further details of Develop Preliminary Scientific Plan, Develop Financial 
Contractual Plan, Develop Preliminary Admin Plan, and Develop Admin Plan business 
use cases, respectively, as shown in Figure 33. 
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Figure 33. Business use cases for to-be Plan Study. 
 
Register Patient Advocate is a new business use case in the Initiate Study category.  
Patient advocates will need to be identified to the electronic systems since they will 
require authorization to access trial data.  Conduct Study-Specific Personnel Training 
must be modified to include patient advocate input.  A summary of additions and changes 
are shown in Figure 34.   
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Figure 34. Business use cases for to-be Initiate Study. 
 
Four new business use cases need to be created for Conduct Study.  They are Refer 
Subject, Monitor Subject, Monitor Trial Data, and Provide Health Education.  A fifth 
business use case, Monitor Study has been created, as a convenience, to aggregate the 
monitoring use cases.  A summary of additions and changes are shown in Figure 35. 
 
One new use case, Obtain Trial Data, needs to be created for Report and Analyze Study, 
as shown in Figure 36.  This use case will generate patient and trial views of data in 
response to ad hoc requests from trial subjects and patient advocates and for general 
reports to the community. 
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Figure 35. Business use cases for to-be Conduct Study. 
 
 
Figure 36. Business use cases for to-be Report and Analyze Study. 
 
Manage Post-Study business use cases will address activities that are performed to 
maintain community trust after a study has completed.  Disseminate Trial Results targets 
community members, such as community-based research partners, trial subjects and their 
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physicians, patient advocates, and community leaders.  This is shown in Figure 37. 
 
 
Figure 37. Business use cases for Manage Pre-/Post-Study. 
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Appendix H  New Business Actors, Business Models, and Business Use Cases 
 
Although not part of RUP/SOMA, the Service Identification task to refine a business use 
case should be applied to new use cases.  New business actors should be defined, 
business models should be refined, and business use cases defined in sufficient detail to 
be realized.  
 
A. Business Actors. 
Business use case analysis yielded new actors, Patient Advocate Coordinator, 
Community Member, and Community Outreach Coordinator.  Brief descriptions of each 
actor are provided below: 
• The Patient Advocate Coordinator is responsible for recruiting, training, and 
managing patient advocates and community healthcare providers. 
• A Community Member can be a community leader, a community-based 
healthcare provider, community healthcare providers, or potential trial subjects 
and their families. 
• The Community Outreach Coordinator is responsible for general outreach 
activities to media, policy makers, community leaders and members, and 
healthcare providers-in-training.  
 
B. Business Model Refinement. 
The business models for Manage Patient Advocates and Refer Subject have been further 
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refined, as shown in Figure 38 and Figure 39.   
 
 
Figure 38. Refinement of Manage Patient Advocates business use case. 
 
 
Figure 39. Refinement of Refer Subject business use case. 
 
C. Detailed Business Use Cases. 
Details for each business use case to be implemented follow. 
  
135 
 
UC0001:  Recruit Patient Advocate 
 
Participating Actors:  Patient Advocate Coordinator 
 
Description:  Maintain contact information for a healthcare provider (e.g., enrolling physician) or 
a patient advocate.  Information can be added, changed, displayed, or deleted. 
 
Preconditions: 
1. User is authorized to perform read, create, update, and delete participants. 
2. User has accessed the application logon page. 
 
Postconditions:  An entry for an advocate has been read, created, updated, or deleted. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log into the 
system. 
  
 2 The system requests user 
authorization / authentication. 
 
  3 Return authorization 
/ authentication status. 
 4 The system displays the Patient 
Advocates page showing a list of 
processing options. 
 
5 If the user chooses to add an 
advocate 
  
 5.1 The system displays a form to 
collect information.  
 
5.2 The user enters the required 
information and submits a request. 
  
 5.3 The system verifies that the form 
fields contain valid data. 
 
 5.4 The system requests to create an 
entry in the Advocates repository. 
 
  5.5 The database 
creates an entry. 
 5.6 The system displays a message to 
indicate the entry was created 
successfully. 
 
6 If the user chooses to review, 
update, or delete 
  
 6.1 The system displays options to 
process a single entry or multiple 
entries. 
 
6.2 If the user chooses to process 
from a list of advocates from the 
repository 
  
 6.2.1 The system requests to retrieve 
all entries in the Advocates repository. 
 
  6.2.2 The database 
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retrieves all entries. 
 6.2.3 The system displays the results, 
sorted in alphabetical order by last 
name. 
 
6.2.4 The user selects one of 
advocates to process and submits a 
request to review, update or delete. 
  
6.3 If the user chooses to process a 
single entry 
 
 
 
 6.3.1 The system displays a form to 
enter the name of the advocate. 
 
6.3.2 The user updates the form and 
submits a request to update or delete. 
  
 6.3.3 The system verifies that the form 
fields contain valid data. 
 
 6.4 The system requests to retrieve the 
entry in the Advocates repository for 
the requested advocate. 
 
  6.4.1 The database 
retrieves the entry.  
 6.4.2 The system displays the current 
data for the advocate. 
 
6.5 If the user chooses to change 
information about an advocate 
  
6.5.1 The user updates the form and 
submits a request. 
  
 6.5.2 The system verifies that the form 
fields contain valid data. 
 
 6.5.3 The system requests to update 
the entry in the Advocates repository. 
 
  6.5.4 The database 
updates the entry 
 6.5.5 The system displays a message to 
indicate the entry was updated 
successfully. 
 
6.6 If the user chooses to delete an 
advocate from the repository 
  
6.6.1 If the user confirms delete   
 6.6.2 The system requests to delete the 
entry from the Advocates repository. 
 
  6.6.3 The database 
deletes the entry. 
 6.6.4 The system displays a message to 
indicate the entry was deleted 
successfully. 
 
6.6.5 If the user cancels delete   
 7 The system displays the Patient 
Advocates page. 
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UC0002:  Register Patient Advocate 
 
Participating Actors:  Patient Advocate Coordinator 
 
Description:  Assign a patient advocate to an active trial.  Information can be added, changed, 
displayed, or deleted. 
 
Preconditions: 
1. User is authorized to perform read, create, update, and delete participants. 
2. User has accessed the application logon page. 
 
Postconditions:  Advocate has been added or dropped from a clinical trial. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log into 
the system. 
  
 2 The system requests user authorization / 
authentication. 
 
  3 Return authorization 
/ authentication status. 
 4 The system displays the Patient Advocates 
page with options to process a single entry or 
multiple entries. 
 
5 If the user chooses to process 
from a list of advocates from 
the repository 
  
 5.1 The system requests to retrieve all entries 
in the Advocates repository. 
 
  5.2 The database 
retrieves all entries. 
 5.3 The system displays the results, sorted in 
alphabetical order by last name. 
 
5.4 The user selects one of 
advocates to process and 
submits a request to register or 
drop. 
  
6 If the user chooses to process 
a single entry 
 
 
 
 6.1 The system displays a form to enter the 
name of the advocate. 
 
6.2 The user updates the form 
and submits a request to 
register or drop. 
  
 6.3 The system verifies that the form fields 
contain valid data. 
 
 7 The system requests to retrieve the entry in 
the Advocates repository for the requested 
advocate. 
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  8 The database 
retrieves the entry.  
 9 If the request is to register, the system 
requests to retrieve a list of active trials from 
the Trials repository. 
 
 10 If the request is to drop, the system 
requests to retrieve a list of trials associated 
with the advocate from the Trials repository. 
 
  11 The database 
retrieves the list. 
 12 The system displays the current data for 
the advocate. 
 
13 If the user chooses to 
register the advocate for one or 
more trials 
  
 13.1 The system requests to update the entry 
in the Advocates repository. 
 
  13.2 The database 
updates the entry 
 13.3 The system displays a message to 
indicate the entry was updated successfully. 
 
14 If the user chooses to drop 
an advocate from an active trial 
  
 14.1 The system requests to update the entry 
in the Advocates repository. 
 
  14.2 The database 
updates the entry 
 14.3 The system displays a message to 
indicate the entry was updated successfully. 
 
 15 The system displays the Patient 
Advocates page. 
 
 
 
UC1001:  Manage Trial Candidate 
 
Participating Actors:  Patient Advocate 
 
Description:  Maintain information required to refer a subject for a clinical trial.  A trial 
candidate and information associated with that subject can be added, changed, displayed, or 
deleted.  Once all required information is completed, a request can be submitted  
 
Preconditions: 
1. User is authorized to perform read, create, update, and delete information about trial 
candidates. 
2. User has accessed the application logon page. 
 
Postconditions:  An entry for a trial candidate has been read, created, updated, or deleted. 
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Main Success Scenario 
Actor System Resource 
1 The user requests to log into the 
system. 
  
 2 The system requests user authorization 
/ authentication. 
 
  3 Return authorization 
/ authentication status. 
 4 The system displays the Trial 
Candidates page showing a list of 
processing options. 
 
5 If the user chooses to add a 
candidate 
  
 5.1 The system displays a form to collect 
information.  
 
5.2 The user enters the required 
information and submits a request. 
  
 5.3 The system verifies that the form 
fields contain valid data. 
 
 5.4 The system requests to create an 
entry in the Candidates repository. 
 
  5.5 The database 
creates an entry. 
 5.6 The system displays a message to 
indicate the entry was created 
successfully. 
 
6 If the user chooses to review, 
update, or delete 
  
 6.1 The system displays options to 
process a single entry or multiple entries. 
 
6.2. If the user chooses to process 
from a list of candidates from the 
repository 
  
 6.2.1 The system requests to retrieve all 
entries in the Candidates repository 
associated with the advocate. 
 
  6.2.2 The database 
retrieves all entries. 
 6.2.3 The system displays the results, 
sorted in alphabetical order by last name. 
 
6.2.4 The user selects one of 
candidates to process and submits 
a request to refer or drop. 
  
6.3 If the user chooses to process 
a single entry 
 
 
 
 6.3.1 The system displays a form to enter 
the name of the candidate. 
 
6.3.2 The user updates the form 
and submits a request to update or 
delete. 
  
 6.3.3 The system verifies that the form 
fields contain valid data. 
 
  
140 
 
 6.4 The system requests to retrieve the 
entry in the Candidates repository for the 
requested candidate. 
 
  6.4.1 The database 
retrieves the entry.  
 6.4.2 The system displays the current 
data for the candidate. 
 
6.5 If the user chooses to change 
information about a candidate 
  
6.5.1 The user updates the form 
and submits a request. 
  
 6.5.2 The system verifies that the form 
fields contain valid data. 
 
 6.5.3 The system requests to update the 
entry in the Candidates repository. 
 
  6.5.4 The database 
updates the entry 
 6.5.5 The system displays a message to 
indicate the entry was updated 
successfully. 
 
6.6 If the user chooses to delete a 
candidate from the repository 
  
6.6.1 If the user confirms delete   
 6.6.2 The system requests to delete the 
entry from the Candidates repository. 
 
  6.6.3 The database 
deletes the entry. 
 6.6.4 The system displays a message to 
indicate the entry was deleted 
successfully. 
 
6.6.5 If the user cancels delete   
 7 The system displays the Trial 
Candidates page. 
 
 
 
UC1002:  Request Subject Referral 
 
Participating Actors:  Patient Advocate 
 
Description:  Request to refer a subject to an active trial.  Information can be added or changed. 
 
Preconditions: 
1. User is authorized to perform read, create, update, and delete participants. 
2. User has accessed the application logon page. 
 
Postconditions:  Advocate has been added or dropped from a clinical trial. 
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Main Success Scenario 
Actor System Resource 
1 The user requests to log into 
the system. 
  
 2 The system requests user authorization / 
authentication. 
 
  3 Return authorization 
/ authentication status. 
 4 The system displays the Trial Candidates 
page with options to process a single entry 
or multiple entries. 
 
5 If the user chooses to process 
from a list of candidates from 
the repository 
  
 5.1 The system requests to retrieve all 
entries in the Candidates repository 
associated with the advocate. 
 
  5.2 The database 
retrieves all entries. 
 5.3 The system displays the results, sorted 
in alphabetical order by last name. 
 
5.4 The user selects one of 
candidates to process and 
submits the request. 
  
6 If the user chooses to process 
a single entry 
 
 
 
 6.1 The system displays a form to enter the 
name of the candidate. 
 
6.2 The user updates the form 
and submits a request to 
retrieve. 
  
 6.3 The system verifies that the form fields 
contain valid data. 
 
 7 The system requests to retrieve the entry 
in the Candidate repository for the 
requested candidate. 
 
  8 The database 
retrieves the entry.  
 9 The system requests to retrieve a list of 
active trials from the Trials repository 
associated with the advocate. 
 
  10 The database 
retrieves the list. 
 11 The system displays the current data for 
the candidate and processing options 
 
12 If the user chooses to view 
trial information 
  
 12.1 The system requests to retrieve trial 
information from the Trials repository. 
 
  12.2 The database 
retrieves the 
information. 
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 12.3 The system displays trial information 
and processing options. 
 
13 The user chooses to refer the 
candidate for the trial or to drop 
the candidate. 
  
 13.1 The system requests to update the 
entry in the Candidates repository. 
 
  13.2 The database 
updates the entry. 
 13.3 The system displays a message to 
indicate the entry was updated 
successfully. 
 
 14 The system displays the Trial 
Candidates page. 
 
 
 
UC1003:  Manage Referral Request 
 
Participating Actors:  Site Registrar 
 
Description:  Review trial candidate referrals and approves or rejects for registration. 
 
Preconditions: 
1. User is authorized to review trial candidate referrals. 
2. User has accessed the application logon page. 
 
Postconditions:  A trial candidate has been reviewed, accepted, or rejected for a clinical trial. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log into 
the system. 
  
 2 The system requests user authorization / 
authentication. 
 
  3 Return authorization / 
authentication status. 
 4 The system displays the Trial 
Candidates page with options to process a 
single entry or multiple entries. 
 
5 If the user chooses to process 
from a list of candidates from 
the repository 
  
 5.1 The system requests to retrieve all 
entries in the Candidates repository 
associated with the advocate. 
 
  5.2 The database 
retrieves all entries. 
 5.3 The system displays the results, 
sorted in alphabetical order by last name. 
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5.4 The user selects one of 
candidates to process and 
submits the request. 
  
6 If the user chooses to process 
a single entry 
 
 
 
 6.1 The system displays a form to enter 
the name of the candidate. 
 
6.2 The user updates the form 
and submits a request to 
retrieve. 
  
 6.3 The system verifies that the form 
fields contain valid data. 
 
 7 The system requests to retrieve the 
entry in the Candidate repository for the 
requested candidate. 
 
  8 The database retrieves 
the entry.  
 9 The system requests to retrieve a list of 
active trials from the Trials repository 
associated with the advocate. 
 
  10 The database 
retrieves the list. 
 11 The system displays the current data 
for the candidate and processing options 
 
12 If the user chooses to view 
trial information 
  
 12.1 The system requests to retrieve trial 
information from the Trials repository. 
 
  12.2 The database 
retrieves the information. 
 12.3 The system displays trial 
information and processing options. 
 
13 The user chooses to accept 
the candidate for the trial or to 
accept the candidate. 
  
 13.1 The system requests to add the 
patient to the trial. 
 
  13.2 The Patient service 
adds the candidate. 
 13.3 The system requests to register the 
patient in the trial  
 
  13.4 The Registration 
service registers the 
candidate. 
 13.5 The system displays a message to 
indicate the entry was updated 
successfully. 
 
 14 The system displays the Trial 
Candidates page. 
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UC2001:  Monitor Subject – Study Subject 
 
Participating Actors:  Study Subject 
 
Description:  Review trial data for the study subject and submit questions to researchers. 
 
Preconditions: 
1. User is authorized to the system. 
2. User has accessed the application logon page. 
 
Postconditions:  Trial data has been viewed, a question has been submitted, or a response has 
been viewed. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log into 
the system. 
  
 2 The system requests user authorization 
/ authentication. 
 
  3 Return authorization / 
authentication status. 
 4 The system displays a list of 
processing options. 
 
5 If the user chooses to 
retrieve data 
  
 5.1 The system requests to retrieve trial 
data for the user from the Trial Data 
database. 
 
  5.2 The database retrieves 
the trial data. 
 5.3 The system displays the trial data.  
6 If the user chooses to submit 
a question 
  
 6.1 The system displays a form for the 
question. 
 
6.2 The user enters the 
question on the form and 
submits it. 
  
 6.3 The system requests the question to 
be posted in the Communications 
database.  
 
  6.4 The database creates an 
entry. 
 6.5 The system displays a message 
indicating the question has been posted. 
 
7 If the user chooses to 
retrieve communications 
  
 7.1 The system requests to retrieve all 
communications for the user. 
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  7.2 The database retrieves 
all communications. 
 7.3 The system displays 
communications and a menu of options. 
 
7.4 If the user chooses to view 
a selected communication 
  
 7.4.1 The system displays the 
communication in a pop-up window. 
 
7.4.2 The user closes the 
window. 
  
 8 The system displays the Trial 
Monitoring page. 
 
 
 
UC2002:  Monitor Subject – Enrolling Physician 
 
Participating Actors:  Enrolling Physician 
 
Description:  Review trial data for the patients who are participating in a study and submit 
questions to researchers. 
 
Preconditions: 
1. User is authorized to the system. 
2. User has accessed the application logon page. 
 
Postconditions:  Trial data has been viewed, a question has been submitted, or a response has 
been viewed. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log 
into the system. 
  
 2 The system requests user authorization / 
authentication. 
 
  3 Return authorization 
/ authentication status. 
 4 The system displays the Trial Monitoring 
page with options to process a single entry or 
multiple entries. 
 
5 If the user chooses to 
process from a list of 
patients from the repository 
  
 5.1 The system requests to retrieve all entries 
in the Candidates repository that are registered 
for one or more trials and are associated with 
the enrolling physician. 
 
  5.2 The database 
retrieves all entries. 
 5.3 The system displays the results, sorted in 
alphabetical order by last name. 
 
  
146 
 
5.4 The user selects one of 
patients to process and 
submits the request. 
  
6 If the user chooses to 
process a single entry 
 
 
 
 6.1 The system displays a form to enter the 
name of the patient. 
 
6.2 The user updates the 
form and submits a request 
to retrieve. 
  
 6.3 The system verifies that the form fields 
contain valid data. 
 
 7 The system requests to retrieve the entry in 
the Candidate repository for the requested 
candidate. 
 
  8 The database 
retrieves the entry.  
 9 The system requests to retrieve a list of trials 
from the Trials repository associated with the 
patient. 
 
  10 The database 
retrieves the list. 
 11 The system displays the current trials for the 
patient and processing options 
 
12 If the user chooses to 
retrieve trial data 
  
 12.1 The system requests to retrieve trial data 
for the patient from the Trial Data database. 
 
  12.2 The database 
retrieves the trial data. 
 12.3 The system displays the trial data.  
13 If the user chooses to 
submit a question 
  
 13.1 The system displays a form for the 
question. 
 
13.2 The user enters the 
question on the form and 
submits it. 
  
 13.3 The system requests the question to be 
posted in the Communications database.  
 
  13.4 The database 
creates an entry. 
 13.5 The system displays a message indicating 
the question has been posted. 
 
14 If the user chooses to 
retrieve communications 
  
 14.1 The system requests to retrieve all 
communications for the user. 
 
  14.2 The database 
retrieves all 
communications. 
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 14.3 The system displays communications and 
a menu of options. 
 
14.4 If the user chooses to 
view a selected 
communication 
  
 14.4.1 The system displays the communication 
in a pop-up window. 
 
14.4.2 The user closes the 
window. 
  
 15 The system displays the Trial Monitoring 
page. 
 
 
 
UC2003:  Monitor Trial Data 
 
Participating Actors:  Enrolling Physician, Community Member 
 
Description:  Review summary trial data and submit questions to researchers. 
 
Preconditions: 
1. User is authorized to the system. 
2. User has accessed the application logon page. 
 
Postconditions:  Summary trial data has been viewed, a question has been submitted, or a 
response has been viewed. 
 
Main Success Scenario 
Actor System Resource 
1 The user requests to log into 
the system. 
  
 2 The system requests user authorization / 
authentication. 
 
  3 Return authorization / 
authentication status. 
 4 The system displays a list of processing 
options. 
 
5 If the user chooses to 
retrieve data 
  
 5.1 The system requests to retrieve trial 
data from the Trial Data database for the 
associated user. 
 
  5.2 The database retrieves 
the trial data. 
 5.3 The system displays the trial data.  
6 If the user chooses to 
submit a question 
  
 6.1 The system displays a form for the 
question. 
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6.2 The user enters the 
question on the form and 
submits it. 
  
 6.3 The system requests the question to be 
posted in the Communications database.  
 
  6.4 The database creates 
an entry. 
 6.5 The system displays a message 
indicating the question has been posted. 
 
7 If the user chooses to 
retrieve communications 
  
 7.1 The system requests to retrieve all 
communications for the user. 
 
  7.2 The database retrieves 
all communications. 
 7.3 The system displays communications 
and a menu of options. 
 
7.4 If the user chooses to 
view a selected 
communication 
  
 7.4.1 The system displays the 
communication in a pop-up window. 
 
7.4.2 The user closes the 
window. 
  
 8 The system displays the Trial 
Monitoring page. 
 
 
 
UC2004:  Obtain Trial Data 
 
Participating Actors:  Enrolling Physician, Community Member 
 
Description:  Reports for members of the community, including interim reports on trial subjects, 
interim reports on the overall trial, and final reports on trial outcomes.  The reports allow trial 
subjects to monitor their progress and make decisions about their participation; they allow 
enrolling physicians to monitor their patient’s progress; and they keep members of the 
community engaged.   
 
Preconditions: 
1. User is authorized to the system. 
2. Reports have been pre-defined. 
 
Postconditions:  The report has been provided. 
 
 
UC3001:  Disseminate Trial Results 
 
Participating Actors:  Community Outreach Coordinator 
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Description:  This process describes the steps for obtaining trial outcome reports and distributing 
them to members of the community.   
 
Preconditions: 
1. User is authorized to the system. 
 
Postconditions:  A report has been distributed. 
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Appendix I  Petri Net for Monitor Subject Application 
 
Figure 40 shows a Petri net representing the flow of the Monitor Subject application.  
Annotations are noted in Table 36.  This application is complex in that it requires 
invocation of several internal and external web services.  A Petri net can be used to 
validate this part of the solution. 
 
 
Figure 40. Petri net for Monitor Subject. 
 
Table 36. Annotations for Monitor Subject. 
Place /  
Transition 
Interpretation Description 
P0 User Not logged in 
P1 Web Page Application logon page (web server is available) 
P2 Data List of authorized users  
P3 User Logged in 
P4 Web Page Monitor Subject page 
P5 Service Connection to Confirm Patient Advocate Status 
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P6 Data Request to Register Patient Advocate 
P7 Service Connection to Register Patient Advocate 
P8 Data Patient Advocate Status 
P9 Service Connection to Confirm Subject Status 
P10 Data Request to Confirm Subject Status 
P11 Service Connection to Registration 
P12 Data Subject Status 
P13 Service Connection to Obtain Trial Data 
P14 Data Trial Data 
T0 Task Log in user 
T1 Task Display Monitor Subject page (home page) 
T2 Task Obtain connection to Confirm Patient Advocate Status service; 
submit request to service 
T3 Task Obtain connection to Register Patient Advocate; submit request to 
service 
T4 Task Release connection to Register Patient Advocate; return patient 
advocate status 
T5 Task Release connection to Confirm Patient Advocate Status; return 
patient advocate status 
T6 Task Obtain connection to Confirm Subject Status; submit request to 
service 
T7 Task Obtain connection to Registration; submit request to service 
T8 Task Release connection to Confirm Subject Status; return subject 
status 
T9 Task Release connection to Registration; return subject status 
T10 Task Obtain connection to Obtain Trial Data 
T11 Task Release connection to Obtain Trial Data; return data 
T12 Task Log out user 
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Appendix J  Glossary of Terms 
 
caBIG Cancer Biomedical Informatics Grid.  This platform and 
infrastructure is used by the National Cancer Institute to integrate 
and ensure interoperability among various systems designed to 
manage cancer research. 
 
CDMS Clinical Data Management System.  This system is used by clinical 
researchers to manage data associated with one or more clinical 
trials. 
 
COTS Commercial Off-the-Shelf Software. 
 
CRO Contract Research Organization.  This organization performs 
research activities on behalf of a client. 
 
CRUD Create, Read, Update, Delete.  This acronym is used to describe 
basic functions typically associated with software data. 
 
CTMS Clinical Trial Management System.  This system is used by 
clinical researchers to manage the clinical trials process. 
 
CTS Clinical Trial Suite.  This is a CTMS that is developed by the 
National Cancer Institute. 
 
Design Model This is a document used during the Specification phase of the 
RUP/SOMA methodology to model the high-level design of a web 
service.  Refer to Appendix E for more details about its content. 
  
KPI Key Performance Indicator.  This is a metric that is used to 
measure the performance of a process or tool. 
 
NIH National Institute of Health. 
 
Petri net This is a modeling notation that can be used to represent 
asynchronous and concurrent processes. 
  
RUP Rational Unified Process.  This is a software development process 
that describes how requirements are transformed into software. 
 
Service Model This is a document that is used throughout all phases of the 
RUP/SOMA methodology to model a web service.  Refer to 
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Appendix E for more details about its content. 
 
SOA Service-Oriented Architecture.  This is an architectural style that 
focuses on building discrete, reusable services. 
 
SOMA Service-Oriented Modeling and Architecture.  This is a 
methodology developed by IBM for defining and implementing an 
SOA. 
 
Type 1 dependency SOMA defines a Type 1 dependency as a functional dependency.  
When Service A is composed of Service B and Service C, it has 
Type 1 dependencies on both Service B and Service C. 
 
Type 2 dependency SOMA defines a Type 2 dependency as a temporal dependency.  
When Service A can only be invoked after Service B has been 
executed, it has a Type 2 dependency on Service B. 
 
UML Unified Modeling Language.  This is a visual modeling language 
that can be used to describe software systems. 
